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Huntington’s disease (HD) is a fatal neurodegenerative disorder resulting from a CAG repeat 
expansion in the first exon of the gene encoding the Huntingtin protein (Htt) with physical, 
emotional, and cognitive symptoms. Current standard-of-care regimens for HD are limited to 
symptom-mitigating therapies with little potential for increasing the overall quality of life. As such, 
there is an imminent need for the development of more effective treatment options, efforts for 
which are enabled by a greater understanding of the molecular basis of disease initiation, 
progression, and pathology. Alterations in numerous signal transduction pathways in HD result 
from aberrant kinase signaling. 
 Protein phosphorylation is catalyzed by a class of enzymes called kinases, the cellular 
complement of which is referred to as its kinome. The kinases responsible for driving the fate of 
phosphoproteomes are central to elucidating various complex cellular events. The interactive 
capacity of the phosphate group makes the phosphorylated protein versatile in communicating. 
The study of kinome led to the development of a high throughput screening tool, peptide arrays. 
The arrays were exposed to lysates from cells / tissues where in the kinases from them 
phosphorylate the peptide spotted on the arrays. The degree of phosphorylation is measured for 
each spot on the array and compared to the controls thereby determining the upregulation or 
downregulation of signaling pathways in response to different biological treatments or conditions. 
The online tools used were a data analysis pipeline, Platform for Integrated, Intelligent Kinome 
Analysis-2 (PIIKA 2), and pathway analysis pipeline InnateDB. The kinases regulating the 
significantly (de)phosphorylating peptides were predicted through an online tool NetworKIN 
which utilized the output from PIIKA 2.  
 Peptide arrays were utilized to identify the dysregulated kinase signaling in a) Neural stem 
cells (NSC) using a previously designed array with 298 peptides b) R6/2 HD mouse model across 
key developmental  time points using customized arrays with 1268 peptides. In an effort to 
investigate disease-associated changes in signal transduction activity, global patterns of kinase 
activity (kinome analysis) were characterized within a NSC line derived from a patient with a 
confirmed diagnosis of HD. As indicated by kinome analysis and independently verified by 
phosphorylation-specific antibodies, cytoskeletal signaling, and in particular 
LIMK1/cofilin/slingshot signaling, was dysregulated in HD NSC’s. GSK3β was reported as a 
iii 
 
major upstream kinase potentially activated in the HD NSCs by NetworKIN analysis, an online 
tool. These changes in cytoskeletal associated signaling align with differences in dendrite 
formation between NSCs from HD and age-/sex-matched healthy controls (HC). Dendrites in the 
HD NSCs were 25% shorter relative to dendrites in control NSCs. The peptide array technique 
was then applied to R6/2 HD mouse model using the lysates from 8 key developmental time points 
(Embryonic 9 and 14; at birth; weeks 3, 4, 5, 7, 10) from both sexes.  The subsequent confirmation 
of PIIKA 2 enhanced data transformation followed by pathway analysis revealed cytoskeletal 
dynamics as significantly dysregulated temporally. Changes in upstream regulators ROCK2 and 
PAK were prominent in the embryonic time points and LIMK1/cofilin/slingshot along with 
profilin showed alterations in the later time points especially the 3w and 4w, when the mutant 
huntingtin protein (mHtt) appears in the striatum the most affected cell type in HD brain. 
Collectively, these data highlight the potential role of cytoskeletal dynamics in HD pathology and 
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1. REVIEW OF THE LITERATURE 
 
The main focus of this literature review are the important aspects of Huntington’s disease and the 
kinome analysis utilized to understand the dysregulated kinase signaling.  
 
1.1 Neurodegenerative disorder with polyglutamine repeats 
        
Huntington’s Disease (HD) is one of nine known neurodegenerative disorders (Table 1.1)       
with a polyglutamine (polyQ) expansion in their respective disease - causing protein (Pennuto et 
al., 2009; Stoyas and La Spada, 2018) (Figure 1.1). HD is a progressive, autosomal dominantly 
inherited neurological disorder characterized by prominent motor, psychiatric, and cognitive 
disturbances resulting from the degeneration of striatal neurons (Haddad and Cummings, 1997). 
The other eight members of the CAG-polyglutamine disease family include spinal and bulbar 
muscular atrophy (SBMA), dentatorubral pallidoluysian atrophy, and six spinocerebellar ataxias 
(SCA 1, 2, 3, 6, 7, and 17) (Budworth and McMurray, 2013). All CAG - polyglutamine diseases 
are dominantly inherited, with the exception of SBMA, which is X-linked. The polyglutamine tract 
is believed to be the cause of the toxic gain of function of proteins that lead to the degeneration 
and death of specific neurons, mentioned in the Table 1.1. In HD striatal degeneration is the main 
cause of the disease process, but other structures such as the cortical and hippocampal neurons are 
also affected by mutant huntingtin (mHtt) (Landles and Bates, 2004). The intriguing aspect of 
polyglutamine disorders is that they all affect a specific subset of neuronal population, the 
mechanisms of which are poorly understood, which complicates studies identifying suitable 
therapeutic options (Cattaneo et al., 2001; Fischbeck, 2001; Thomas, 2006).  
 
1.1.1 CAG repeats in Huntington disease  
 
The timing of onset of HD is determined by length of polyglutamine repeat. In the normal 
population, the Htt repeat size varies from 17-29. The expansion of CAG repeats beyond 39 causes 
the expanded polyQ sequence in the protein (Gusella et al., 1983; Orr and Zoghbi, 2007). The 
defect in HD is the expansion of an unstable DNA segment containing polymorphic trinucleotide 
cytosine-adenine-guanine (CAG) repeats in the coding sequence. One copy of mHtt from either 
parent is sufficient to cause the disease. Repeats between 27-35 are referred to as intermediate  
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Table 1.1: List of CAG trinucleotide repeat disorders, genes involved, repeat size and tissues 
affected (Permission to use from Stoyas and La Spada, 2018). 
 





Huntington’s Disease Htt  6–35 36–250  Medium spiny neurons of 
striatum and cortical 
projection neurons  
Spinal and bulbar 
muscular atrophy 
AR  5-34  37-70  Lower motor neuron in 
spinal cord and bulbar 
region of brainstem  
Dentatorubral 
pallidoluysian atrophy  
Atrophin-1  7-35  49–88  Brainstem, cerebellar and 
deep midbrain structures  
Spinocerebellar ataxia 1 Ataxin-1  6–44  39–83  Atrophy, gliosis and severe 
loss of Purkinje cells in 
cerebellum  
Spinocerebellar ataxia 2 Ataxin-2  13–33  32–77  Purkinje and granule cells 
and gliosis of inferior olive 
and pons 
Spinocerebellar ataxia 3 Ataxin-3  12–40  54–89  Spinocerebellar tract, 
brainstem and spinal cord  
Spinocerebellar ataxia 6 Ataxin-6 4–18  19–33  Cerebellar atrophy, loss of 
Purkinje cells and cerebellar 
granule cells  
Spinocerebellar ataxia 7 Ataxin-7  4–35  37–306  Retinal photoreceptors, 
cerebellar cortex, dentate 
nucleus, inferior olive and 
pontine nuclei  
Spinocerebellar ataxia17 TBP  25–42  43–66  Cortex, striatum and 




alleles, whereas 36-39 is incomplete penetrance and beyond 39 is referred to as complete 
penetrance (Chandra et al., 2014). The repeat size is responsible for pathogenesis and individuals 
with higher repeats show earlier and more severe signs of the disease. Offspring of an HD parent 
have a 50% chance of inheriting the disease and there is an inverse relationship between the age 
of onset and the CAG repeat size (Figure 1.1). Notably a recent study pointed out that an 
uninterrupted sequence of CAG repeats is supposedly the most important factor in predicting the 
age of onset of HD (Genetic Modifiers of Huntington's Disease Consortium. Electronic address 





Figure 1.1: The length of CAG repeat is inversely related to the age of onset. 
This is a schematic of the how age of onset is determined by the number of CAG repeats. The 
normal gene contains ≤ 26 CAG repeats (purple). The intermediate allele contains 27-35 repeats 
(blue), but there is incomplete penetrance between 36-39 (yellow). HD is inevitable if the repeat 









1.1.2  Huntington disease: discovery and prevalence  
 
Huntington’s disease was first described by George Huntington an American physician, in 
1872 after studying several affected individuals. As mentioned earlier HD polyQ expansion is 
attributed to a defect in a single gene - huntingtin (Htt) (Bertram and Tanzi, 2005). The median 
life expectancy after the onset of symptoms of the disease is approximately 21.4 years (Foroud et 
al., 1999). Symptoms generally manifest in the fourth or fifth decade of life. Juvenile HD (JHD) 
accounts for 5-10% of all HD cases, and symptoms can occur even before the age of 21 (Quigley, 
2017) (Figure 1.2). The polyQ repeat length is generally more than 60 in JHD, and such individuals 
do not survive more than 10-15 years after the onset of symptoms (Koutsis et al., 2013; Quigley, 
2017). The prevalence of HD is higher in the European population, compared to the East Asian 
population, and affects 5-7 individuals per 100,000 worldwide (Pringsheim et al., 2012) and one 





Figure 1.2: Juvenile HD (JHD) accounts for 5-10% of all HD cases. 
Symptoms of juvenile HD occur in the late teens when the repeats size is more than 55. The adult 






The discovery of the huntingtin gene was after more than 100 years of the first 
comprehensive description of adult-onset of the disease. The Huntington’s Disease Collaborative 
Research Group (HDCRG) discovered the HD gene after 10 years of research (MacDonald et al., 
1993). The gene locus was mapped to chromosome 4p16.3 in the early 1980’s, but it was first 
cloned in 1993 (MacDonald et al., 1993). The disease is caused by mutation in the gene, IT15 
(interesting transcript 15), containing 67 exons encoding a 3144 amino acid protein called 
“huntingtin” or “Htt”. The mutation is an expanded trinucleotide repeat region in exon 1 of 
huntingtin (Htt).  
 
1.1.3 Striatum: structure and function  
 
HD is caused due to the degeneration of neurons in the striatum. In spite of the ubiquitous 
presence of Htt in neurons, it is uncertain why the striatal medium spiny neurons are principally 
vulnerable to the mHtt. The basal ganglia is comprised of the striatum, globus pallidus, 
subthalamic nuclei and substantia nigra. The circuitry of the basal ganglia is complex with multiple 
parallel loops that control and modulate cortical output. Striatum is the major receptive component 
of the basal ganglia, containing three nuclei, namely caudate, putamen and nucleus accumbens 
(Figure 1.3). The first to degenerate in HD is the caudate nucleus followed by putamen and then 
the nucleus accumbens in the later stages of the disease. The striatum has inhibitory GABAergic 
(Gamma aminobutyric acid) neurotransmitters. Almost 90% of the striatal neurons are medium 
spiny neurons that express GABA, while about 10% are interneurons. Apart from this, the striatum 
also widely expresses dopamine receptors. Cortico-striatal neurons and thalamo-striatal inputs are 
glutaminergic and afferents from the substantia nigra and the ventral tegmental area are 
dopaminergic (Andre et al., 2010). 
The primary function of the striatum is the regulation of motor movements and the 
organization of motor activity requires multiple synaptic inputs from the cortex, midbrain and 
thalamus. The striatum regulates both motor and non-motor activities such as cognition, language, 







Figure 1.3: Striatum is the major receptive component of the basal ganglia. 
This schematic represents the location of striatum in the human brain. Striatum consists of two 




1.1.4 Gain of function vs neurodevelopmental disease 
 
There are two concepts of neuronal degeneration, one the classic concept and second the 
neurodevelopmental concept of degeneration (Figure 1.4). The classic theory of HD is that the 
mHtt results in a gain-of-function and the toxicity is responsible for neuronal cell death. 
Conversely, the loss-of-function of normal Htt in tandem with the increase in mHtt accelerates the 
process. The current perception is that mHtt causes the disease due to accumulation of the toxic 
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protein in the cell, which ultimately leads to degeneration (Bowater and Wells, 2001; La Spada et 
al., 1994; Orr and Zoghbi, 2007). Htt-deficient mice die early during embryonic development, 
while Htt +/- mice exhibit no or few neurological abnormalities therefore, emphasizing the gain-
of-function as the cause of toxicity (Duyao et al., 1995; Nasir et al., 1995). 
 
        
 
 
Figure 1.4: Models of degeneration in HD. 
Schematic of the similarities / differences in classic and developmental concepts leading to 
degeneration in HD. Classic concept of degeneration suggests that normal neuron degenerates in 
the disease process due to the effect of mutant HD gene. Developmental concept is based on 
aberrant development, where the disease process begins with abnormal neuronal development, 
compensation leads to a mutant steady state, and degeneration occurs due to stress caused by 







Another theory is that the role of Htt in normal neural development is compromised due to 
mHtt, which is in itself a part of the disease process (Kerschbamer and Biagioli, 2015; Wood, 
2018).  The individual is able to deal with the toxic effects of the mHtt while there is sufficient 
normal Htt to balance the molecular changes. Eventually the balance tips in favor of mHtt due to 
maturation and aging processes, and this drives the faulty circuit towards degeneration. The 
developmental model needs further validation by experiments which are able to recapitulate the 
prodromal stage of the disease. Accurate identification of signaling changes in the earliest 
symptomatic stages of HD might lead to better biomarkers or therapeutic targets in treating HD.   
       
1.1.5 Huntingtin protein expression and function  
 
            Htt is ubiquitously expressed but the specific vulnerability of striatal medium spiny 
neurons is unexplained.  Htt is also expressed in various tissues outside the central nervous system 
(CNS) (Carroll et al., 2015). A subset of the neural population is vulnerable to environmental 
changes and toxins, which ultimately promotes the loss of specific neuronal populations. Ring et 
al performed a transcriptomic analysis utilizing the HD NSC model which revealed a dysregulation 
of genes involved in neuronal development and the formation of the dorsal striatum (Ring et al., 
2015), possibly suggesting the specificity of striatal degeneration. Multiple studies have shown 
that normal Htt is required for development and its importance in cell cycle, neuronal survival and 
stability (Schulte and Littleton, 2011). These functions are affected during the disease process as 
depicted in figure 1.5 resulting in altered protein folding, transcriptional dysregulation, aberrant 
interactions affecting the cytoplasmic processes and activation of apoptosis (Dayalu and Albin, 
2015; Harjes and Wanker, 2003; Landles and Bates, 2004; Li and Li, 2004b). It has been shown 
that the Htt-deficient mice are embryonically lethal at day 8.5, whereas heterozygous mice display 
fewer neuronal anomalies therefore indicating its importance during development and survival 
(Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995). Huntingtin is a large protein that is 
ubiquitously expressed throughout the body, but its function still remains unknown though it has 
more than 200 known interacting partners (Parsons et al., 2014; Schulte et al., 2011; Tourette et 
al., 2014).  
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Figure 1.5: Schematic of a neuron depicting pathways dysregulated in HD. 
Mutant huntingtin protein is involved in altered protein folding, autophagic inhibition, 
transcriptional dysregulation, axonal impairment, aberrant interactions affecting the cytoplasmic 
processes, mitochondrial toxicity and activation of apoptosis. 
      
      
 
 
1.1.6 Structure of huntingtin protein and post-translational modifications on the protein 
 
The Huntington protein is 3,144 amino acids with a mass of 348 kilo-Daltons and is 
expressed ubiquitously in the body - most of which is in the cytoplasm. It is a well conserved 
protein from flies to mammals, though most similarity occurs in mammals (Saudou and Humbert, 
2016). The function of normal Htt in neurons is unknown, although it has been associated regularly 
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with synaptic transmission, neurogenesis, apoptotic cell death, transcription, axonal transport and 
has 3235 interacting partners (Schulte et al., 2011; Szebenyi et al., 2003; Tourette et al., 2014; 
Trushina et al., 2003; Velier et al., 1998). The gene consists of 67 exons and the polyQ tract [(Q(n)] 
begins at the 18th amino acid. In humans, the polyQ domain is followed by two proline rich regions 
[P(n)], whereas in mice, this number is six (Li and Li, 2004b; Saudou and Humbert, 2016) (Figure 
1.6). The Htt protein contains HEAT (huntingtin, elongation factor 3, the PR65/A subunit of 
protein phosphatase 2A and lipid kinase Tor) repeat sequences. Each HEAT repeat is comprised 
of a 50 amino acid sequences and there are 28-36 such repeats in the Htt protein (Li and Li, 2004a). 
The HEAT repeats have a helical structure, which forms super helical structures with hydrophobic 
cores. These repeats are predicted to mediate various inter- and intra-molecular interactions, many 
of which are dissociated by proteolysis (Palidwor et al., 2009). Bioinformatics analysis between 
amino acids 60 and 3,144 reported 16-36 HEAT repeats that are also required for protein-protein 
interactions (Palidwor et al., 2009; Takano and Gusella, 2002; Tartari et al., 2008; Warby et al., 
2008). Notably the domain organization of Htt by cryo-electron microscopy and their data 
indicated three domains, including N, C and a smaller bridge domain (Guo et al., 2018). Proteins 
involved in microtubule dynamics possess HEAT repeats, which indicate that the repeats might 
play an important role in protein-protein interactions (Imarisio et al., 2008). Structural studies have 
reported that Htt is an elongated superhelical solenoid with a diameter of ~200 Å (Colin et al., 
2008; Li and Li, 2004a) The N-terminal region is best studied as it contains the most vulnerable 
polyQ stretch and the rest of the protein is not as well characterized, which includes 66 amino 
acids 69 to 3,144, accounting for 97.8% of the protein (Schulte and Littleton, 2011). Apart from 
HEAT repeats there are four PEST - amino acids proline (P), glutamic acid (E) or aspartic acid 
(D), serine (S) and threonine (T) - domains containing proteolytic site (Ehrnhoefer et al., 2011; 
Warby et al., 2008). Both the wild type (WT) and mHtt contain proteolytic sites, and HD patient’s 
show an increase in the proteolytic activity, which leads to the generation of multiple small N-
terminal fractions containing polyQ repeats (Lecker et al., 2006; Miller et al., 2010). The N-
terminal 17 amino acids are conserved in vertebrates (Tartari et al., 2008). This region consists of 
an amphipathic α-helix which is critical for its maintenance in the endoplasmic reticulum (Atwal 
et al., 2007). The main function for this region is the nuclear export signal (NES), which is also a 
target for multiple post-translational modifications (PTM) affecting the clearance of Htt and its 
subcellular localization (Atwal et al., 2007) (Saudou and Humbert, 2016).  
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Htt undergoes multiple PTMs, including phosphorylation, acetylation, palmitoylation, 
ubiquitination and sumoylation. PTMs influence the aggregation, cellular properties, and toxicity 
of mHtt and therefore may contribute to HD pathogenesis (DeGuire et al., 2018; Gauthier et al., 
2004). The Htt protein has several known phosphorylation sites as highlighted in Figure 1.6. These 
are well known sites for phosphorylation of the Htt protein and most are hypo-phosphorylated in 
the mHtt compared to the WT protein and the reduced phosphorylation has been associated with 





Figure 1.6: Schematic representation of Htt protein and its PTMs. 
The schematic of the Htt protein represents from the N to the C terminus. Phosphorylation sites at 
threonine (T) or serine (S) residues are indicated in yellow. Polyglutamine tract is represented as 
Q(n) and polyproline as P(n). The HEAT domains are represented as blue cylindrical structures 






1.1.7 Cytoskeleton: structure and function 
 
            The cytoskeleton is a network of protein-like fibers inside the cell, which help in 
maintaining its structure and function. These scaffolding networks help organize other intracellular 
components and enable transport within the cell. There are various components of the 
cytoskeleton, including actin (microfilaments), microtubules (MT) and intermediate filaments 
(IF). They are highly organized and well-coordinated structural features in normal cells. They are 
involved in major functions such as cellular movement, cell division and intracellular transport, 




            Microfilaments are composed of actin polymers and multiple actin-binding proteins 
(ABP). Actin exists in two forms, monomeric or globular (G-actin) and polymeric or filamentous 
(F-actin), and binds to ATP which upon hydrolysis to ADP leads to the growth of the filament. 
Actin filaments are arranged in double helical polymers with a tropomyosin (Tm) polymer running 
along the major groove in the microfilament (Gunning et al., 2008; Gunning et al., 2015). The 
cellular events that require synchronized turnover and remodeling of actin filaments, such as 
motility, differentiation, division and membrane organization utilize actin microfilaments. These 
actin polymers and Tm interact with ABPs thus, generating a complex that forms the basis of the 




            MTs are composed of α- and β-tubulin heterodimers. Both α- and β-tubulin associate into 
polymers and there exist different isotypes which have tissue- and development-specific 
expression. There are multiple β-tubulin isotypes that are evolutionarily conserved across species, 
but differ predominantly in their carboxy-terminal region. This region binds to multiple 
microtubule associated proteins (MAP) and is predicted to influence the MT activity and stability. 
The main function of the MTs are cellular growth, vesicular transport and mitosis. They are highly 
dynamic structures and their ability to polymerize and depolymerize in a regulated manner allows 
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the proper segregation of chromosomes during mitosis. The assembly and disassembly of MTs 
occurs by GTP hydrolysis only on the β-tubulin subunit, not the entire α / β heterodimer (Akhshi 
et al., 2014; Fife et al., 2014).  
 
1.1.7.3 Intermediate filaments  
 
            IFs can be formed from 40 different protein subunits and are structurally different from the 
well-conserved globular proteins, actin and tubulin. IFs are divided into five different categories, 
including keratin, neurofilament, desmin, laminin and vimentin (Robert et al., 2016). This 
categorization is based on the protein composition and its intracellular localization. IFs can extend 
from around the nucleus across the cytoplasm and be attached to the extracellular matrix (ECM) 
thus, forming an extensive network. This intricate network allows the coordination of 
multifunctional cytoskeletal activities by relaying information from within the cell to the exterior 
(Chang and Goldman, 2004).   
        The major function of the aforementioned cytoskeletal units is to maintain cell structure and 
motility. Altered cellular motility has been recently viewed as a hallmark feature of various 
neurodegenerative disorders. The process of cell motility can be broken down into four steps: 
protrusion, adhesion, contraction and retraction (Figure 1.7) (Fife et al., 2014). Extracellular 
signals such as growth factors and chemokines generate a gradient that polarize the cell movement. 
The integrins, receptor tyrosine kinases (RTK) and cadherins after receiving these signals alter the 
activity of downstream Rho GTPase guanine nucleotide exchange factors (GEFs) which finally 
affect Rho GTPases which are the key players in regulating cytoskeletal dynamics (Jaffe and Hall, 
2005). The extension of the actin filaments towards the extracellular signal is stabilized by the 
adhesions linking actin to the ECM proteins (Hall, 2012). This allows the protrusion and the 
adhesion of the cytoskeletal proteins toward the signal by various protein-protein interactions. The 
contraction allows the disassembly of the entire subset of proteins at the distal end of the cell 
thereby allowing the movement of the cell body forward and at the same time retracting the cell 
body and pushing it in the direction of cell movement (Hall, 2012).  Rho GTPases are a family of 
20 small G proteins regulating the cytoskeletal proteins and thereby influencing the cell cycle, cell 
polarity and cell migration (Jaffe and Hall, 2005). Rho GTPases function as a molecular switch 
where the GDP-bound form is inactive and the GTP-bound form is active (Jaffe and Hall, 2005). 
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The regulation of mammalian GTPases is complex since its inactivation is regulated by 67 GTPase 
proteins and inactivation by 82 GEFs, which act downstream of cell surface receptors (Rossman 
et al., 2005). There are three well studied Rho GTPases, including Rho, Rac and Cdc42, which 
regulate actin assembly. Cdc42 is involved in the regulation of microtubule dynamics (Hall, 2012). 
Rho can recruit ROCK (Rho kinase) family kinases which are responsible for phosphorylating 
multiple cytoskeletal proteins (Hall, 2012; Jaffe and Hall, 2005). These interactions are involved 
in promoting actin stress fibre formation where another player cofilin is involved. Cofilin is 
downstream of the Rho GTPase pathway and along with the actin-related protein 2/3 (ARP2/3) 
complex, plays an important role in the generation of free actin filament ends thus resulting in 
actin filament remodeling by polymerization and depolymerization (Hall, 2012). Cofilin is 
inactivated when phosphorylated by LIM kinase 1 (LIMK1) and reactivated by dephosphorylation 
by a phosphatase Slingshot (SSH1L) (Mouneimne et al., 2006; Soosairajah et al., 2005). LIMK is 
downstream of the Rho GTPase effector proteins and its activity is highly regulated by the 
phosphorylation of the Rho kinases (ROCK1 and ROCK2) (Nakagawa et al., 1996). Cofilin 
activity is tightly regulated and is required for chemotaxis (directed cell movement towards a 
chemoattractant), and for the reorganization of actin filaments, which move toward 
chemoattractant such as growth factors (Mouneimne et al., 2006). Ultimately ROCK signaling 
influences cytoskeletal dynamics by phosphorylating the downstream targets, LIMK (LIMK1 and 
LIMK2), which along with its interaction with cofilin and the phosphatase SSHL (SSHL1 and 
SSHL2), probably determines the cellular response to a stimulus (Mouneimne et al., 2006; 











Figure 1.7: The cell cytoskeleton. 
The schematic representation of the process of cell motility is broken down into four steps: 
protrusion, adhesion, contraction and retraction (1-4). F-actin is shown in purple (short, branched 
F-actin at the leading edge, and long, unbranched F-actin stress fibres at the rear). Microtubules 
are shown in blue. Cytoskeletal regulatory and associated proteins ROCK, LIMK and cofilin/ADF 
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1.1.7.4 Cytoskeletal abnormalities in Huntington’s Disease    
                
            Neurons have two cytoplasmic extensions, including axons and dendrites and they require 
a specialized cytoskeleton to maintain their complex morphology in order for neural transmission 
to occur through these processes (Figure 1.8). A change in their neural morphology may affect the 
neural function and ultimately induce pathology. In neurons, the dynamic tubulin polymers are 
stabilized before forming axonal and dendritic extensions (Mitchison and Kirschner, 1988). The 
neuronal projections transport cargo bi-directionally along the microtubules, partnering along with 
the kinesins and motor proteins (Goldstein and Yang, 2000; Liot et al., 2013). It is believed that 
mHtt interacts with the motor proteins that carry cargo, such as TrkB-containing vesicles, and 
reduces its interaction with the microtubules, which affects transport (Gauthier et al., 2004; Li et 
al., 1998). A number of studies utilizing HD mouse models (R6/1, R6/2, Q175 and KI140) have 
reported an increased tau phosphorylation involving the kinases that regulate it, including GSK3 
and CamKII (Fernandez-Nogales et al., 2015; Gratuze et al., 2016). GSK-3β is the major kinase 
to phosphorylate tau both in vitro and in vivo and a major microtubule-associated protein (Medina 
et al., 2011). CamKII on the other hand is involved in activating the major phosphatase SSH1L 
which dephosphorylates cofilin thereby activating it (Zhao et al., 2012). As discussed earlier the 
LIMK1, cofilin and SSH1L are involved in actin cytoskeletal reorganization.  The levels of cofilin 
which is an upstream regulator of actin are perturbed in a number of neurodegenerative disorders 
such as AD, PD and Amyotrophic Lateral Sclerosis (ALS) (Eira et al., 2016; Sainath and Gallo, 
2015). There are a number of stressors in the cell that cause actin cytoskeletal dynamic arrest. Rod 
formations are seen in AD and PD and the activated cofilin saturates the actin filaments during 
stress and bundles them into rod-like structures, thereby ceasing actin polymerization and 
depositing these rods in the nucleus and cytoplasm (Minamide et al., 2000; Zhao et al., 2006). This 
process leads to the release of free ATP in the cell and once the stress is released, the rods dissociate 
almost immediately. Additionally, profilin (an actin binding protein), which has an opposite action 
to cofilin, is perturbed in ALS (Henty-Ridilla et al., 2017; Kiaei et al., 2018). Profilin has the 
opposite action to cofilin on actin, and binds to Htt at a proline-rich region adjacent to the expanded 
polyQ tract (Henty-Ridilla et al., 2017; Zhao et al., 2006). Thus, a number of studies have shown 
stress-related actin rod formation in a variety of neurodegenerative disorders, despite that the 





Figure 1.8: Schematic of neuronal structure and its cytoskeleton. 
Neurons have a highly regulated cytoskeleton with actin, microtubules and intermediate filaments 
which are localized differently on the dendrites, spine and cell body (A), axon (B, C and D) and 
synapse and growth cone (E). Actin rings are seen across the axon and actin arcs form the structural 
basis of the synaptic end. Actin meshwork is found especially concentrated in the dendrites and 
the synaptic end. Actin trails are concentrated mostly in the axon. Microtubules are predominantly 
in the axon but they are also present in the dendrites and synapse. Intermediate filaments localized 







embryonically lethal although one study suggested that the postnatal neurons in the forebrain 
showed that cofilin was required for the turnover of F-actin at the synapses (Gurniak et al., 2005). 
An increase in calcium levels activate calcineurin (CaN), which dephosphorylates cofilin through 
the activity of the phosphatase, slingshot (SSH1L) (Zhao et al., 2006). Therefore, a normal neuron 
requires proper cofilin functioning, which must be tightly regulated by upstream kinases and 
phosphatases (Bamburg and Bernstein, 2010). Thus among many other roles in the cell, Htt 
appears to be involved in key molecular interactions involving vesicular transport between the 
actin and microtubule cytoskeletons (Caviston and Holzbaur, 2009). 
       
1.2 Phosphorylation mediated cellular signaling  
  
Protein phosphorylation is a significant PTM that regulates the dynamics of a protein allowing 
precise temporal control of its structure, function, and subcellular localization.   
 
1.2.1 Kinases  
 
            Alterations in numerous signal transduction pathways in HD result from aberrant kinase 
signaling. The balance between kinase signaling pathways is important to maintain normal cellular 
processes, such as proliferation, neuronal plasticity, apoptosis, etc. Protein kinases have the ability 
to phosphorylate other proteins and regulate their function. Phosphorylation occurs through the 
addition of a phosphate group (PO4) by a mechanism controlled by kinases. There are 518 human 
protein kinases classified according to the amino acid residue that they phosphorylate. The most 
phosphorylated residues are serine (Ser or S; 86.4%), threonine (Thr or T; 11.8%) and tyrosine 
(Tyr or Y; 1.8%). Once activated, these protein kinases lead to the phosphorylation of other 
proteins. Most of the kinases act on both serine and threonine (serine /threonine kinases; STKs), 
while others act on only tyrosine (tyrosine kinases; TKs). Phosphatases have the opposite function 
of kinases, and remove the phosphate group from the phosphoproteins. They hydrolyze the 
phosphoric acid monoesters into a phosphate group and a molecule with a free hydroxyl group. 
There are about 226 protein phosphatases that regulate phosphorylation events. A number of 
cellular molecules are activated and deactivated by phosphorylation / dephosphorylation events 
due to specific kinases and phosphatases acting on them, respectively. 
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1.2.2 Kinome and phosphoproteome  
 
            Cellular phosphorylation analyses can be divided into i) kinome and ii) phosphoproteome. 
The former focusses on the analysis of the protein kinases mediating phosphorylation, while the 
latter focusses on the targets of those kinases. The kinases responsible for driving the fate of 
phosphoproteomes are central to elucidating various complex cellular events. As discussed in the 
previous section cellular signaling events are largely controlled by phosphorylation / 
dephosphorylation thus play an important role in different cellular processes. Recent advances 
have facilitated studies of the global effects of phosphorylation, as well as studies of specific 
signaling pathways. This has been performed by mass spectrometric methods where after the 
enrichment of phosphorylated peptides/proteins, different methodologies such as ionization and 
fragmentation have been utilized for the mass-analysis of phosphorylated peptides. The 
physiological substrates for protein kinases are proteins and the specificity of the target is dictated 
by the conserved amino acid residues surrounding the phosphorylation site. Such conserved 
peptide sequences have been used in peptide arrays designed to study whole proteins by kinome 
analysis. The Vmax (the maximum rate at which an enzyme can catalyze a reaction) and Km (the 
amount of substrate required for the enzyme to function at one half of its maximal rate) values are 
close to the natural substrates thus providing the ideal platform for studying these proteins. These 
peptides are chemically stable and easily produced commercially. They can be printed on glass 
slides and are cost effective, making them easily available for research studies.  
 
1.3. Kinome profiling 
 
            The early 2000’s marked the completion of the human genome project and a simultaneous 
review published in Science listed the protein kinase complement of the human genome and 
termed it the “Kinome” (Manning et al., 2002).  Protein phosphorylation by protein kinases (PK) 
is the most characterized signaling mechanism in eukaryotic cells. The majority of cellular proteins 
are phosphorylated, making this one of, if not the most important modification in cellular 
processes. As many as one-third of all the proteins are phosphorylated at any given time, which 
makes it a difficult undertaking to enumerate all such proteins. It can be simplified by looking at 
the substrates that each kinase phosphorylates in the human kinome. This can then be extrapolated 
to physiological and diseased states to gain a better understanding to provide therapeutic benefits 
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(Johnson and Hunter, 2005). A comparative analysis of genomes has determined that there are 
considerable differences among eukaryotes. The differences are highlighted by the variance in the 
number of kinases present in their genomes. For example the Arabidopsis thaliana genome 
contains 610 kinases, Drosophila melanogaster has 239 kinases, Saccharomyces cerevisiae has 
115 kinases, and Plasmodium falciparum has 65 kinases (Peppelenbosch, 2012). The human 
kinome constitutes ~518 members (1.7% of  protein coding genes) (Johnson and Hunter, 2005), 
of which the mouse has 510 orthologs, which accounts for ~98% similarity (Caenepeel et al., 
2004).  Exploiting array technology for the development of drug targets for biologically important 
kinases has been utilized in large-scale screening processes. The most challenging aspect is that 
the appropriate kinase substrates have to be recognized and printed on the array, which is based 
on a literature search and examinations of online databases. The specificity of the kinase to 
phosphorylate the substrate produces a dataset that can be mined for unknown biological functions 
and potential drug targets in different diseases (Arsenault et al., 2011; Arsenault et al., 2012a; Guo 
et al., 2014a; Jalal et al., 2009; Sutherland et al., 2013). Kinome analyses via peptide arrays have 
proven effective in understanding signaling events associated with a number of diseases, including 
neurodegenerative disorders such as prion (Arsenault et al., 2012b) and Alzheimer’s disease 
(Hoozemans et al., 2012), cancer (Goel et al., 2018; Labots et al., 2016; Moser et al., 2014; Parikh 
and Peppelenbosch, 2010), infectious diseases (Kindrachuk et al., 2014; Mulongo et al., 2014; 
Robertson et al., 2014; Van Wyk et al., 2016), and inflammation (Arsenault et al., 2013a; 
Arsenault et al., 2013b). 
 
1.3.1 Peptide arrays 
 
            Peptide arrays were first developed in 1984, when they were synthesized on packed 
polyethylene rods  (Geysen et al., 1984). Protein can range from a few amino acids to hundreds of 
amino acids. The very short sequences of about 40-50 amino acids are referred to as peptides. 
Some of the current peptide array technologies are based on the concept of light-directed, spatially 
addressable chemical synthesis which was introduced in 1991 (Fodor et al., 1991). SPOT synthesis 
(Synthetic peptide arrays on membrane supports) was developed in parallel in 1992 with the 
preparation of a series of predefined, chemically synthesized short peptide sequences on absorptive 
surfaces (Frank, 2002). Peptide arrays are an efficient technique with easy to synthesize peptides 
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that are regularly used to investigate PTMs in vitro. It is a simple, but powerful method to 
investigate PTMs by utilizing their intensity values after staining to study a treatment sample 
compared to a control in a rapid and cost effective manner. 
 




            DAPPLE (http://saphire.usask.ca/saphire/dapple/) is a web based platform developed for 
phosphorylation site determination to predict the additional mouse phosphorylation events based 
on described phosphorylation events of other species (Trost et al., 2013a) alongside the known 
human and mouse phosphorylation events based on published literature. A simple workflow of 
DAPPLE 2 shows that it predicts sites for different post-translational modifications in the 
proteome of the target organism selected and generates a list of predicted PTMs (Figure 1.9). The 
list for HD peptide array included over 270,000 peptides which were rationally selected and 
shortlisted to 1268 peptides providing an overall coverage of the major signaling pathways 






Figure 1.9: DAPPLE pipeline. 
The flowchart shows that DAPPLE 2 predicts sites for post-translational modifications in the 
proteome of the target organism selected (input) and generates a list of predicted PTMs (output). 






1.3.2.2 Peptide array design 
 
            The array was designed by utilizing these unique peptide sequences, with a biological 
significance based on the literature. Custom peptide synthesis and printing was completed on a 
glass slide, and each array measured approximately 7.6 cm long and 2.5 cm wide as manufactured 
by JPT Peptide Technologies (https://www.jpt.com/) (Figure 1.10). The peptides are typically 15 
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amino acids long with the phosphoacceptor residue in the center, flanked by an equal number of 
residues on either side. Peptide array was divided into three grids / blocks of same set of peptides 
and each printed nine times (three in each block), making sure that that there was no margin for 
error and there are enough technical replicates for statistical analysis. Each spot on the array 
contains many copies of the peptide sequence which is determined by the manufacturer. Ideally 
each peptide should have a central phosphoacceptor residue with the conserved sequence on either 





Figure 1.10: Overview of array design. 
(A) Physical presentation of the peptides. Each spot on the array represents a different peptide 
sequence presented within a grid of the total population of peptides (kinase substrates) to be 
considered. Each grid is replicated three times to generate technical replicates of each spot. Dark 
gray spots on the edge of the grid represent control peptides for better visualization. (B) Peptides 
on the array. Each spot on the array represents a population of single peptides (typically 15 amino 
acids long) in which the central position is the phosphoacceptor residue represented here in green 
(Permission to use from Daigle et al., 2014).  
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on the array or by having more residues on one side. Each peptide spot measured about 350µm in 
diameter and was separated by a distance of about 750 µm. The peptide spotting was in a grid 
fashion surrounded by full length proteins and were printed on the periphery to aid in better 
visualization. The exact layout of arrays differ based on the peptides printed on it which can be 
from hundreds to thousands. The design and printing is completed by the commercial providers. 
The laboratory procedure for using these arrays are described in section 3.4. After the scanning the 
spots appear to be like as shown in Figure 1.11 A where the black spots are the one with little or 
no phosphorylation and spots with phosphorylation are green (Figure 1.13 B). The values of these 
emitted light intensities are read by an image scanner and are called “intensity values”. The stain 
binds non-specifically to the background hence the intensity values around the spot are considered 
as background values. The background intensity is subtracted from the foreground intensity (spot 
intensity value) and the resulting value indicates the level of phosphorylation of that particular 
peptide. It is difficult to measure the absolute levels of the phosphorylation with peptide arrays 
hence for any significant biological output from both treatment and control arrays are required.  
The treatment array minus control array intensity values can be used to determine the amount of 
phosphorylation of the peptide under study. Such peptide is termed as a “differentially 
phosphorylated” peptide and indicates whether the peptide is hyper- or hypo-phosphorylated when 
compared to control. The technical replicates mentioned earlier evaluate the random variation in 
the biological experiment. The same peptide is spotted three times in each block therefore there 
are nine in total across the three blocks and are termed as intra-array replicates. The technical 
replicates have three advantages i) phosphorylation measure of each peptide is averaged hence 
reducing random variation ii) peptides with random variation can be identified iii) these technical 
replicates check for the variation in the measurement of phosphorylation across different biological 
samples. Hence the sample size is important for determining the biological significance of a 
particular treatment / disease. The larger the sample size, the more definitive is the peptide array 
output since the variation in the different biological backgrounds due to treatment/ genetic 
background or any other anomaly does not lead to a potential data bias in the clustering pattern. 
The raw intensities obtained from the kinome dataset are normalized before meaningful 





Figure 1.11: Scanned image of a kinome microarray after incubation with cell lysate followed 
by staining.  
(A) The scanned image of a complete array. (B) Black spots contain peptides that underwent little 













1.3.3 Bioinformatic pipeline 
 
1.3.3.1 Platform for Intelligent, Integrated Kinome Analysis (PIIKA 2) 
 
            PIIKA 2 was designed to identify differentially phosphorylated peptides in the peptide 
arrays (Trost et al., 2013b) (Figure 1.12). It was designed using a software program in the R 
environment. The input files contain the raw intensities from the genepix microarray and the output 
can be represented as t-test values or other visual representations, such as PCA plots, heatmaps, 
etc. The output files contain multiple column subheadings, but P-value and fold change (FC) were 
utilized which are considered to identify significantly differentially phosphorylated peptide (Li et 
al., 2012). A t-test indicates the difference in the mean phosphorylation between the treatment and 
control but does not indicate the directionality / degree of difference (+/-), hence fold change. A 
liberal cut off (P ≤ 0.1/0.2 and FC > 1) is used in kinome analyses to generate a large data set and 
avoid false positives. The P-value used for the cell line data was 0.1 and for the mouse model 0.2 
which was based on the number of peptides printed in the array. The peptide array used for cell 
lines had 298 unique peptides and the mouse study used peptide array with 1268 peptides, hence 
the leniency in the P-value. T-test was performed using the R environment function in PIIKA 2, 
to generate the P-values taking into account the intensity values between the same peptides under 
treatment and control conditions. FC gives the magnitude of differences between the 
phosphorylation in the treatment and control. The pathway analysis software (InnateDB) uses both 
FC and P-value to determine the significant pathways dysregulated in the peptide array. PIIKA 2 
uses the difference (not ratio) between the treatment and control to generate the FC. The 
transformed intensities are converted to FC values by using the formula: 
 
Fold change = 2d     [where, d = average treatment – average control] 
 
A comparative analysis of various normalization methods (normalization by log2 (Log2), 
percentile normalization (PNorm), quantile normalization (QNorm), transformation by variance 
stabilization (vsn) (Huber et al., 2002) was performed for normalizing the dataset thereby not 
altering the data relevance, verifying that vsn transformation is the best in preserving the raw data 
patterns. The raw data after processing by vsn revealed that it had the same distribution pattern as 





Figure 1.12: A general workflow of the software pipeline (PIIKA) for kinome analysis. 
The flow of information and activity starts from the top left and follows the arrows. Rectangles 
with green background represent procedures, and the one with blue background represents 
intermediate results. The differentially phosphorylated peptide list was generated by comparing 
the test to control followed by normalization. This was used for all further bioinformatics analyses   





of vsn. First, to normalize all measurements on the same scale and second to convert all negative 
intensity values to positive using a complex algorithm. To determine a significant differentially 
phosphorylated peptide, both the FC and the corresponding P-value are considered. This is because 
the FC could be due to a few (or one) significantly (de)phosphorylated peptides and a t-test P-
value is required to confirm the replicate consistency. Finally, the FC and P-value should be used 




            While t-tests determine whether the individual peptides are differentially phosphorylated 
and fold change determines the directionality of the change, pathway analysis determines whether 
the entire pathway is differentially modulated. This was done by another online tool InnateDB. 
InnateDB is equipped to analyze peptide array dataset and once the list of peptides is uploaded 
along with the P-value, FC and uniprot ID, this information is used to generate a list of biological 
pathways that are significantly upregulated or downregulated. InnateDB 
(https://www.innatedb.com/) is a platform that facilitates the analysis of mammalian, murine and 
bovine genes (Breuer et al., 2013). It contains close to 200,000 molecular interactions that are 
experimentally validated, with 3000+ pathway annotations that allow a better understanding of the 
input dataset. In addition to these it also has 18000+ manually-curated interactions. InnateDB can 
be queried for specific pathways or in a high throughput fashion, incorporating multiple genes/ 
protein dataset to perform a more complex analysis. Gene ID’s are accepted from Uniprot, 
Ensembl, Ref Seq, Entrez gene in the InnateDB software. It can be used as a knowledgebase to 
perform pathway analyses, gene ontology analyses, and network analyses, among other search 
fields. All such interactions can be downloaded as visual tools, as well as in text-based formats 
(tab, csv, xls) to aid the user in interpreting their own data (Breuer et al., 2013). The P-values in 
InnateDB are generated using the hypergeometric distribution test which confirms whether a 
pathway is statistically more over-represented in the uploaded dataset than expected by chance 
prior to correction for multiple testing. P-values are automatically corrected using the Benjamini 
and Hochberg or by a conservative Bonferroni correction. The output generated from InnateDB 
are over-represented pathways associated with the P-values from the input data. Since the 
InnateDB software generates output from various databases there are many canonical pathways 
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represented multiple times. The validation of these peptides is completed independently using 
other assays.  
 
1.4. Neural stem cells in studying Huntington’s disease   
 
            Molecular investigations of disease have benefited from tools such as stem cells, which 
can be differentiated into many lineages, including neuronal (Nelson et al., 2010; Takahashi and 
Yamanaka, 2013), and enable drug screening to expedite the development of therapeutics for 
neurodevelopmental, neurodegenerative, and psychiatric disorders (Ardhanareeswaran et al., 
2017). Recently, the ability to generate induced pluripotent stem cells (iPSCs) from fully 
differentiated cells (such as skin fibroblasts) has opened many avenues for the advancement of 
medicine (Takahashi and Yamanaka, 2013). The precision with which fibroblasts can be 
reprogrammed to develop neuronal stem cells (NSCs) that form fully functional neurons has 
tremendous potential for screening potential treatments of neurodegenerative disorders (Ross and 
Akimov, 2014). Importantly, NSCs can be generated from HD patients within virtually all age-
groups, rendering a convenient model to study the age-related pathogenesis of the disease 
(Koyuncu et al., 2018; Ross and Tabrizi, 2011). Such NSCs can also be exploited to infer patient-
specific therapeutic opportunities (Mu et al., 2014; Ross and Akimov, 2014). Examinations of HD 
NSCs has led to observed differences in cellular pathways pertaining to oxidative stress, 
mitochondrial dynamics, transcriptional dysregulation, and gene expression (Consortium, 2012; 
Szlachcic et al., 2015; Zhang et al., 2010). iPSC models have been generated for other polyQ 
disorders and neurological diseases (Kikuchi et al., 2017; Xie et al., 2016; Yang et al., 2016). 
While iPSC models have been used to examine individual or related signaling cascades (Mueller 
et al., 2018; Nekrasov et al., 2016; Szlachcic et al., 2017), here we examine an HD patient-derived 
NSC line for changes in the patterns of multiple signaling cascades simultaneously using a kinome 
technology refined at our University (Arsenault et al., 2011; Baharani et al., 2017; Jalal et al., 
2009). The stem cells provide an opportunity to assess a neurological disease for which it is tough 
to access the tissue compared to the other tissues of the body. The development of the stem cell 
technology has allowed faster and more clinically relevant progress especially in the field of 




1.5 Mouse models to study Huntington’s disease 
 
To study human disease processes, transgenic mouse models have become a necessity 
(Brouillet et al., 1999; Ferrante, 2009). Neurological disease models should be robust and have 
limited variability in mimicking human diseases. They should possess minimum discrepancies and 
should display similar neural abnormalities as observed in individuals affected with the specific 
neuronal disorder (Beal and Ferrante, 2004; Hersch and Ferrante, 2004).There are a number of 
mouse models used to study HD, and have been grouped in a broader umbrella of genetically 
modified mouse models and chemically induced lesion models. The chemically induced lesion 
models are induced with 3-nitroproprionic acid or quinolonic acid (Ramaswamy et al., 2007). The 
genetically modified mouse models are grouped into three sub-categories based on how they were 
developed. They include N-terminal transgenic animals, full-length transgenic models and knock-
in transgenic mouse models. The N-terminal animals carry the 5´ portion of the human Htt gene 
containing the CAG repeats. The full-length models have the full-length Htt sequence with the 
trinucleotide repeats. The knock-in models have CAG repeats of varying lengths, which are 
directly engineered into the mouse Htt locus. All models are similar in that they contain CAG 
repeats, but show differences in the HD phenotype (Ferrante, 2009; Figiel et al., 2012). The N-
terminal transgenic lines were the first HD mouse models generated and they are the most 
commonly used in HD research. The most studied among them is the R6/2 transgenic mouse 
model. Many preclinical studies have been completed utilizing these lines (Pouladi et al., 2013) 
and it is one of the best characterized transgenic lines available (Mangiarini et al., 1996).  
  
1.5.1 R6/2 mouse model 
 
R6/2 mouse model have a robust phenotype, a shorter life span (3-4 months), and well 
defined neurobehavioral and neuropathological findings hence they are widely used in HD 
research. The R6/2 lines were the first to be generated expressing the mutant human exon Htt 
(Mangiarini et al., 1996). The N-terminal transgenic mice were generated by pronuclear injections, 
and thus, each transgene is integrated randomly at a unique site in the mouse genome. The human 
trinucleotide repeats in these transgenes are unstable, and thus, there is an increase in the number 
of repeats in both germ line and somatic cells in successive generations. Monitoring of the repeat 
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length is critical while maintaining colonies to reduce experimental variation (Cummings et al., 
2012).  
R6/2 mice carry a small section of the 5´ end of human Htt gene, which includes exon 1 
with the CAG trinucleotide repeats. The stock is maintained with a CAG repeat of 120 +/- 5 repeat 
units. The N-terminal lines have a more prominent phenotype than the other mouse models. They 
develop neurological abnormalities more rapidly and show loss of motor coordination, tremors, 
hypokinesis, abnormal gait and premature death (Menalled et al., 2009). The N-terminal mutant 
Htt fragment is sufficient to exhibit HD-like neuropathology in mice. R6/2 mice range in survival 
form 14-21 weeks, depending on the housing conditions (Li et al., 2005; Wood et al., 2010). 
Behavioural studies indicate that R6/2 mice exhibit deteriorating motor performance, reductions 
in body weight, and impaired dystonic movements that worsen with age (Figiel et al., 2012). These 
mice also show a reduce brain weight (around week 4), decreased brain volume and expanded 
ventricles (around week 8.5), which are hallmarks of HD. These mice also exhibit a decrease in 
striatal volume and atrophy of the striatal neurons towards the end stages of disease (Ferrante, 
2009). Htt aggregates increase with age, although they are reported to be present since birth, which 
is not observed in human HD patients. Such observations could be attributed to the presence of the 
truncated gene, which could be responsible for the aggravated phenotype. Similarities exist in the 
dysregulated cellular mechanisms of HD patients and R6/2 mice, including transcriptional 
regulation, proteolysis, apoptosis, mitochondrial function, and vesicular trafficking. R6/2 mice 
have substantial neuropathological similarities with HD patients, but do not have the same 
genetics. Nevertheless these mice have well characterized phenotypes and can be used for survival 
studies and clinical trials generating outcomes in as few as 3 months (Li et al., 2005; Skotte et al., 
2018). R6/2 model exhibits a progressive HD phenotype, which is the closest to the human HD 
symptoms, and therefore, is considered the best model for therapeutic studies. 
 
1.6 Sex differences in neurodegenerative disorders  
 
The potential sex differences in Huntington’s, Parkinson’s and other neurodegenerative 
disorders on the onset of the disease and its progression are poorly understood. Animal models 
provide a great platform to understand the difference between the two sexes in the disease process 
as they allow the circumventing of the problems of standardization, i.e. the variation in the CAG 
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repeats and age matched samples which are difficult to obtain in the human patients. Recently, it 
was shown that these disorders have a bias (Kovtun et al., 2004; Nyarko et al., 2018; Quartey et 
al., 2019; Smith and Dahodwala, 2014; Wooten et al., 2004). The disease susceptibility, 
pathogenesis, and clinical presentation is different in males compared to females (Smith and 
Dahodwala, 2014). Such differences are being attributed to the female sex hormone, estrogen, 
having a protective effect on neurons (Bourque et al., 2009; Siani et al., 2017). The first report to 
comprehensively characterize the behavioral, physiological and neuropathological difference in 
HD mice reported atrophy of DARPP32(+) MSNs only in male transgenic HD rats (Bode et al., 
2008). DARPP32 is expressed in MSNs which also express dopamine D1 receptors. Dopamine is 
a neurotransmitter that controls movement, cognition and emotional functions. The dopamine 
transporter (DAT) membrane receptor is the key regulator of dopamine uptake at the synaptic cleft 
and studies have shown that estrogen has a protective effect in dopaminergic neurons (Cereda et 
al., 2013; Simunovic et al., 2010; van Dyck et al., 1995). Differences in gene expressions between 
male and female brains have also been identified and those changes are anticipated even before 
the effect of the gonadal hormones (Dewing et al., 2003). The male sex-determining region on the 
Y chromosome (SRY) is a transcription factor. In situ hybridization has shown SRY expression in 
the brains of rodents, and subsequent studies revealed that the regions with the highest expressions 
are the cortex, substantia nigra, and medial mammillary bodies (Dewing et al., 2006). SRY exerts 
its influence on the biochemical properties of dopaminergic neurons, which in turn affects motor 
behaviour in male rats (Czech et al., 2012). The loss of SRY in males leads to a significant 
reduction in dopamine function in the surviving neurons hence SRY may be an additional 
mechanism that regulates dopamine in males. Thus, the difference in molecular mechanisms 
between sexes can likely be attributed to the influence of sex chromosome genes (Carruth et al., 
2002; Dewing et al., 2006).  
 
1.6.1 Sex differences in Huntington’s disease  
 
Sex differences have not been well studied in HD with some research directing towards 
severe phenotype in females while the other report the opposite. A report studied the influence of 
sex on HD progression on 1267 patients with HD, wherein women showed slightly more severe 
phenotype and faster rate of progression in women (Zielonka et al., 2013). This study revealed sex 
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differences in the severity of HD, where women exhibited lower motor and functional UHDRS 
(Unified Huntington’s Disease Rating Scale) scores compared to males. UHDRS is an evaluation 
standard used to assess HD based on four clinical performance categories, including motor 
function, cognitive function, behavioral abnormalities, and functional capacity (Huntington, 
1996). Multiple reports also suggested that the age of onset being higher in females than males 
(Roos et al., 1991); however, the progression of disease was milder in women, compared to men 
(Chen et al., 2009; Roos et al., 1991). The loss of body weight has been reported in both males 
and female HD patients, however, the body mass index lower in males despite their higher calorific 
intake.  
The repeats are highly unstable and longer when inherited from an affected father 
(Norremolle et al., 1995). Males predominantly show an expansion of the repeats and the females 
show a contraction (Kovtun et al., 2000). Another study compared 254 affected parent-child pairs 
with HD to determine the frequency of intergenerational CAG changes in the mHtt which reported 
expansions in the polyQ repeats when transmitted through the affected father (Kremer et al., 1995). 
Another study revealed somatic and gonadal mosaicism which indicated towards the mitotic and 
meiotic instability in the polyQ repeats (Telenius et al., 1994). The most neuropathological 
findings in HD are in the brain which exhibited the most somatic mosaicism followed by 
significant mosaicism in the sperm (Telenius et al., 1994). A recent report demonstrated that 
increased age of the father was also associated with a higher frequency of CAG repeat expansions 
in sperm (Wright et al., 2019) which supports previous findings (Chong et al., 1997; Semaka et 
al., 2013).  
Female hormones are being considered as a neuroprotective therapy that delay the onset 
and reduce the severity of HD symptoms (Bode et al., 2008). The overall results of such studies 
indicate that there is a complex sex effect on disease severity and the rate of HD progression 
(Zielonka et al., 2013). There is still a considerable amount of research required to confirm which 
sex is most affected since there is evidence supporting both. This can be addressed if there is an 
inclusion of equal number of females and males in research trials and the dataset compared for 
similarities and differences. The assumption that results from males apply to females could result 
in a bias dataset because it fails to recognize the sex dependent effects in a research study (Beery 
and Zucker, 2011). Thus, such observations should be considered while designing future 
experiments and clinical trials (McCullough et al., 2014).  
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2. HYPOTHESIS AND OBJECTIVES 
 
2.1 Rationale and Hypothesis 
 
            The aberrant kinase signaling in HD has not been well characterized. There are multiple 
pathways that are dysregulated and the alterations might occur due to age, sex and disease 
progression which can be well understood if the differences are recapitulated by a global profiling 
of kinase signaling across all the key developmental time points in both sexes. The use of peptide 
arrays to identify the signaling pathways that are dysregulated in Huntington’s disease will provide 
insight into these pathological mechanisms of the disease as well as rationale targets for therapeutic 
intervention.  
 
         The hypothesis states that multiple processes are dysregulated in HD due to aberrant kinase 




1. To design a HD specific peptide array for kinome analysis. 
2. To identify potential pathways that are dysregulated in striatal tissue from R6/2 HD mice using 
peptide arrays and pathway analysis. 
3. To validate the differentially phosphorylated peptides that are determined from the 
bioinformatic analysis of the peptide array data. 











3. MATERIALS AND METHODS 
 
3.1 Reagents and chemicals 
 
            The regents and chemicals used in the experiments are provided in the Table 3.1 below 
along with the names and addresses of the manufacturer / supplier in Table 3.2. 
 
Table 3.1: List of reagents and/or chemicals. The Table lists commercially procured reagents, 
chemicals and other materials to perform the experiments. The names of the supplier and catalogue 
number are also indicated.  
 
Reagents and Chemicals Supplier and Catalogue Number 
  
(Ethylenedinitrilo) tetra acetic acid, Sigma-Aldrich, E9884 
100 bp ladder NEB, N3231S 
1kb ladder NEB, N3232S 
30% Acrylamide/Bis Solution 29:1 Biorad, 1610156 
Acetonitrile  EMD Biosciences, 200-835-2 
Ammonium Persulfate  Sigma-Aldrich, A3678 
Aprotinin Sigma-Aldrich, P2714 
ATP Sigma-Aldrich,  FLAAS-5VL 
BCA protein assay  Thermo Fisher, 23225 
Bovine serum albumin  Sigma-Aldrich,  05470 
Brij35  Sigma-Aldrich,  8.01962 
Cryovials VWR, 89092-262 
DNA Polymerase Thermo Fisher, F530S 
DNeasy Blood & Tissue Kit Qiagen, 69506 
DPBS- No Ca+2, No Mg+2 Life Technologies, 14190 
Ethyl alcohol  Fisher Scientific, S25310 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetra 
acetic acid 
Sigma-Aldrich,  E3889 
Glycerol  Sigma-Aldrich,  G5516 
Glycine  Fisher Scientific, S80028 
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Human Neural Progenitor Cells (hNPCs) Axol, ax0016 
Huntington's Disease Human Neural Progenitor Cells  Axol ax0211 
Leupeptin Sigma-Aldrich,  L2884 
Lifter slip Fisher Scientific, 22 035 805 
Magnesium chloride  Fisher Scientific, 232-094-6 
Methanol  EMD Millipore, MX0475 
N,N,N´,N´-tetramethylethylenediamine (TEMED) Sigma-Aldrich, T9281 
Neural Maintenance Medium Kit. Axol, ax0031 
Neural Unlock™ Axol, ax0044 
NewBlot Stripping Buffer for Nitrocellulose membrane Li-COR, P/N 928-40030 
Phenylmethylsulfonylfluoride  Thermo Fisher, 36978 
Phosphatase inhibitor Thermo Fisher, 78420 
Phosphatase inhibitor Thermo Fisher, 78428 
Phosphatase inhibitor cocktail 3 Sigma-Aldrich, P0044 
Phusion DNA Polymerase Thermo Fisher, F530S 
Precision Plus Protein™ Dual Xtra Standards Biorad, 161-0377 
Pre-stained protein ladder Biorad,161-0375 
Pre-stained protein ladder Biorad,161-0377 
PRO-Q, Diamond Phosphoprotein Stain Invitrogen, P33300 
Protease inhibitor Thermo Fisher, 78430 
Protein ladder Biorad, 161-0375 
RIPA Lysis Buffer System Santa Cruz Biotechnology, sc24948 
Sodium acetate  Sigma-Aldrich, S2889 
Sodium chloride Sigma-Aldrich, S9888 
Sodium dodecyl sulfate  Sigma-Aldrich, L3771 
Sodium fluoride Sigma-Aldrich, 201154 
Sodium orthovanadate   EMD Millipore, 567540 
Sodium pyrophosphate  Sigma-Aldrich, S6422 
Sure Bond™ Coating Solution Axol, ax0041  
Sure Boost       Axol, ax0045 
Sure Growth  Axol, ax0047 
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Tris base  Fisher Scientific, BP152-5 
Triton X-100  Fisher Scientific, AC215680000 
Trypsin (Cell culture grade)  Fisher Scientific, SV3003101 
Trypsin with EDTA Life Technologies, 25300-054 
Tween-20  Fisher Scientific, BP337500 




Table 3.2: Reagent supplier addresses. This Table lists the names and addresses of all 
reagent/chemical suppliers.   
 
Supplier   Address 
  
Axol Cambridge, United Kingdom 
Bio-Rad   Hercules, California, USA 
Cayman Burlington , Ontario, Canada 
Cell signaling technologies Danvers, Massachusetts, USA 
EMD Millipore Danvers, Massachusetts, USA 
Fisher Scientific Walton, Massachusetts, USA 
Invitrogen Life Technologies Green Island, New York, USA 
LI-COR, Odyssey Lincoln, Newark, USA 
New England Biolabs Ipswich, Massachusetts, USA 
Qiagen Toronto, Ontario, Canada 
Santa Cruz Biotechnologies Santa Monica, California, USA 
Sigma-Aldrich St. Louis, Missouri, USA 
Thermo Fisher Scientific    Logan, Utah, USA 







3.2 Cell culture and tissue harvest 
 
3.2.1 Cell culture harvest 
 
            HD neural stem cells (NSC) with 45 CAG repeats (# ax0021) and iPSC-derived neural 
progenitor control cells (ax0016) were obtained from Axol Biosciences (Cambridge, U.K). Both 
cell lines were cultured according to the vendor’s protocol. Prior to culturing cells, Axol Sure Bond 
coating solution (# ax0041) prepared in 1X PBS (without calcium or magnesium; D-PBS) was 
used to treat uncoated 6-well dishes by incubating in the solution overnight at 37oC. The cells were 
seeded at a density of 10,000-50,000 cells/cm2 in Axol Neural Maintenance Media (# ax0031) 
supplemented with the Axol Sure Boost serum (# ax0045). Following two hours of incubation, the 
media was replaced with neural maintenance media supplemented with the Axol Sure Growth 
serum (# ax0047). Cells were cultured in this media for two days, and thereafter cultured in the 
Neural Maintenance Media alone. For passaging and harvesting cells, the culture dishes were 
rinsed with 1X PBS and cells were detached from the dish using the Axol Neural Unlock solution 
(# ax0044). A total of 10x106 cells were harvested and prepared for either peptide array analysis 
or Western blotting (WB).   
 
3.2.2 Tissue harvest 
 
            The R6/2 HD mouse model expresses a small N-terminal fragment with exon 1 of the 
huntingtin gene (Mangiarini et al., 1996). The fragment contains approximately 120 +/- 5 CAG 
repeats, which generates a progressive (disease) phenotype. The model exhibits many of the 
behavioral and neuropathological features of HD and is well characterized, which makes it a 
perfect candidate for in-depth studies of the HD pathology using kinome analysis. PCR was used 
for genotyping during maintenance of colonies. Brain tissue (whole brain for embryonic and 








3.2.2.1 Genotyping and PCR  
 
            Animal care facility at VIDO-InterVac housed 20 breeding pairs of R6/2 transgenic mice, 
which were purchased from the Jackson Laboratory (#6494). Multiple breeding pairs were 
established between B6CBAF1/J males and ovary-transplanted hemizygous females (Figure 3.1 
and 3.2). Ninety embryos and 169 pups were used for 518 genotyping reactions to confirm both 
the mutant Htt gene and SRY for sex determination. All newborn pups were genotyped and non-
transgenic littermates were used as wild type controls, while presence of SRY was considered as 
male. DNA was extracted using a Qiagen kit (catalog number 60506). DNA extraction was 
completed using the skull from embryonic time points (E19 and E14) after harvesting the brains. 
I obtained ~2mm tail biopsies for the rest of the time points to extract the DNA. The genotype was 
assessed using PCR and amplifications were performed using Phusion DNA polymerase (2 U/µL), 
and dNTP mix with the following reaction and cycling conditions: 
 
Reactions Components (20 µl reaction):  
 
Phusion DNA Polymerase (0.2uL), 10 mM dNTPs, 10 µM Forward Primer (0.2 µM), 10 µM 
Reverse Primer (0.2 µM), Template DNA (<100 ng), 5X Phusion GC Buffer, DMSO (0.6uL), 50 
mM MgCl2 solution, Nuclease-free water (to 20 µl). Cycling Conditions: 
 
 
1. Initial Denaturation                               98 °C (30 seconds)  
35 cycles of  
2. Denaturation                                         98 °C (15 seconds) 
3. Annealing                                             58 °C  (30 seconds)   
4. Extension                                              72 °C  (30 seconds) 
5. Final extension                                     72 °C for 5 minutes 







Figure 3.1: The ovary-transplanted hemizygous female is recommended for breeding with 
B6CBAF1/J males. 
Shown is an ovary-transplanted female with the left ovary (indicated by the forceps) grafted from 
an HD female and the right cauterized to prevent any nonessential pregnancy (Image courtesy: 






Figure 3.2: Shown is the cauterized ovary on the right side (indicated by the forceps) of the 
mouse. 
The embryos in the transplanted ovary on the left are the F1 generation. Such embryos are further 




All PCR primers were purchased from Invitrogen Life Technologies (New York, USA). The 
following primer sequences were used: Forward, 5′-CCG CTC AGG TTC TGC TTT TA-3′; 
Reverse, 5′- TGG AAG GAC TTG AGG GAC TC-3′. The mutant Htt product was ~170 base 
pairs. The forward primer annealed upstream of the CAG repeat region and the reverse primer 
annealed in the transgene; therefore, indicating the presence or absence of the transgene. PCRs to 
determine the sex of pups were also performed under the same reaction conditions. The SRY 
primers were: Forward 5′-TTG TCT AGA GAG CAT GGA GGG CCA TGT CAA-3′; Reverse 5′-
CCA CTC CTC TGT GAC ACT TTA GCC CTC CGA-3′. SRY primers amplified and a product 
of ~ 273 base pair indicated a male sex, since they amplified a region of the Y-chromosome. The 





Figure 3.3: Representative genotyping for HD-positive mice (lanes 1-8) and sex-
determination (lanes 9-16). 
PCR products were generated for various samples (lanes 1-5 and 9-13), for positive control 
reactions from an ovary (lanes 7 and 14) to genotype HD-positive mice and tail snips of a male 
mouse (lane 15) for sex determination. No template controls (lane 8 and 16) were also 
incorporated. A striatum (lane 6) sample from another mouse species was used as a negative 
control. The PCR product size for HD genotypes was ~170 bp and sex determination was ~ 273 
bp.  ST=Striatum; NT=No template; OV=Ovary; F=Female, M=Male, + = presence of mHtt, - 
=absence of mHtt. 
 
 
3.2.2.2 R6/2 developmental time points for tissue harvest   
 
            Age-matched R6/2 breeding pairs were purchased from Jackson Laboratories 
(https://www.jax.org/) and housed in the animal care facility of the Vaccine and Infectious Disease 
Organization - International Vaccine Center (VIDO-InterVac) at the University of Saskatchewan. 
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Animals were maintained with ad libitum access to food and water. The rooms were kept at a 
constant temperature (19°C-22°C) and humidity (40–50%) with a 12:12 h light/dark cycle. The 
breeding scheme included ovarian transplanted hemizygous females with the B6CBAF1/J males. 
R6/2 mice developed a progressive behavioral and neurological phenotype by 4-6 weeks of age, 
which mimics the onset of HD in humans. Both the HD and healthy control (HC) mice were 
grouped into sets of males and females. The different time points for the peptide array analysis 
were embryonic days 9 (E9) and 14 (E14), at birth (P0), and weeks 3 (3w), 4 (4w), 5 (5w), 7 (7w) 
and 10 (10w) (Figure 3.4). The methodology for processing the peptide arrays is described in 
section 3.4. At embryonic time points, whole brains from both HD and HC littermate controls of 
both sexes were dissected and cryopreserved. The striatal tissues were dissected from the brains 
of mice at P0 and weeks 3, 4, 5, 7, 10, and frozen at -80





Figure 3.4: Timeline for peptide array analysis.  
The different time points for the peptide arrays were embryonic days 9 (E9) and 14 (E14), at birth 
(P0), and weeks 3 (3w), 4 (4w), 5 (5w), 7 (7w) and 10 (10w). 
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            Tissues were harvested based on the key developmental time points which were divided 
into eight groups (E9, E14, P0, 3w, 4w, 5w, 7w, and 10w). The time points were chosen based on 
the neural development in the mouse. Embryonic day 9 is the peak of neurogenesis (Darlington et 
al., 1999; Finlay and Darlington, 1995). Embryonic day 14 defines the beginning of the 
development of striatum, caudate and putamen (Fentress et al., 1981). These neurons are the first 
ones to be affected by mHtt leading to the motor abnormalities. The striatum is involved in 
cognition, motor functions, planning and decision making; hence, the degeneration of the striatal 
neurons affects these actions. Neural development was complete at birth, except for the eyes, 





Figure 3.5:  Schematic mouse brain depicting the anatomical location of the striatum. 
Shown is the side and the dorsal views of mouse brains. The location of the striatum is also 
shown in the figure whose neurons are primarily affected in HD. The striatal tissue is located 






(Mangiarini et al., 1996). The 3- and 4-week time points were chosen to include the changes 
appearing in the brain just before the appearance of mHtt. At 5 weeks, the mice showed motor 
impairments (Mangiarini et al., 1996). The loss of body weight was prominent around 7 weeks 
where the HD mice weighed about 60-70% less than their control siblings (Mangiarini et al., 1996). 
The age of onset of HD symptoms is reported to aggravate between 9 and 11 weeks and the end 
point is between 10-13 weeks (Beal and Ferrante, 2004; Mangiarini et al., 1996) . Therefore, the 
inclusion of 10 weeks was the last time point. Overall the selection of time points fell into two 
categories 50% understanding the initial stages of disease progression (E9-3w) and the rest 50% 
to recapitulating the signaling in the course of disease progression (4w-10w). Mice were 
euthanized by cervical dislocation and the brains were removed followed by the dissection of the 
striatum. Whole brains were harvested for embryonic time points (Figure 3.6). All tissues were 
collected in Eppendorf tubes, snap frozen on dry ice and stored at -80oC for peptide array or 
Western blot analyses the details of which are discussed in section 3.4 and 3.5 respectively.  
          


















Figure 3.6: The panel shows the brain tissue harvested from different time points which were 
studied. 
The top row shows the 9-day and 14-day embryos followed by a P0 brain. The rest of the panel 
comprises representative images indicating degeneration in the brain from 3 weeks to 10 weeks in 
both males and females. The first left column are “negative female” (-F) murine brains, i.e., healthy 
control (HC) females without mHtt. This is followed by “positive female” (+F) brain, i.e., with 
mHtt (HD). The following two columns are “negative male” (-M) followed by the extreme right 
column the “positive male” (+M). (Image courtesy VIDO – InterVac Animal care). 
47 
 
3.3 Analysis of neuronal morphology by Neurolucida 360 
 
            Huntington’s disease (HD) and healthy control (HC) neural stem cells (NSCs) were 
cultured in 6-well tissue culture dishes, as described earlier in section 3.2.1. Phase-contrast images 
of both cell lines were acquired at 20x magnification using the Olympus CKX41 light microscope. 
The acquired images were analyzed using Neurolucida 360 software (MBF Biosciences, USA) 
(https://www.mbfbioscience.com/neurolucida360) (Dickstein et al., 2016). Quantitative 
evaluation of HD and HC NSCs morphology was performed, as described previously (Dickstein 
et al., 2016), to determine neurite outgrowth, number of soma, and soma size.  An average of six 
HC and HD fields were analyzed. Each image corresponds to a field from one well of a 6 well 
plate and the data are presented as the mean ± SEM.    
 
3.4 Peptide array technology 
 
            The peptide array technology was used to assess the global kinase profile in both the NSCs 
and the murine tissue. The array used for the cellular kinome profiling was a previously designed 
298 peptide array and I designed the murine array which consists of 1268 peptides. The synthesis, 
spotting and general methodology are described below. 
 
3.4.1. Peptide synthesis and spotting 
 
            The customized peptide microarrays described previously (Jalal et al., 2009) were obtained 
from JPT peptide technologies GmbH (Germany). DAPPLE 2 was used to generate a list of 
270,000 peptides from which a list of 1268 peptides were selected to print on the array. The 
peptides list with the peptide name, uniprot ID, target phosphosite and peptide sequence.  These 
peptides were printed on a modified glass slide in replicates of 9, each measuring ~350 μm with a 
spot concentration of 100 fmol/mm2. The peptides and the corresponding phospho-sites are listed 
in the (Supplementary Table S1) (Figure 3.7). Only the murine proteins (corresponding peptides) 
which have a human homolog were selected. The selection was completed by an in depth analysis 
of the published literature and utilizing web based online databases such as Phosphosite plus 





Figure 3.7: Screenshot of the user interface of the DAPPLE2 web server. 
The target organism and is uploaded and the PTM selected using a dropdown menu. The results 










3.4.2 Processing peptide array 
 
            Briefly, 107 cells, either HD or HC NSCs, were harvested and pelleted by centrifugation at 
7000xg for 10 minutes at 4oC. Murine whole brain (embryonic) and striatal tissue were weighed 
and ice cold kinome lysis buffer was added and allowed to soak for 10 minutes. A hand held 
homogenizer was used for disruption of the cell pellets and tissue. Cells were lysed in freshly 
prepared kinome lysis buffer [20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 mM 
NaF, 1 μg/ml Leupeptin, 1 μg/ml Aprotinin, 1 mM phenylmethylsulphonyl fluoride] and the crude 
lysates were centrifuged at 12000xg for 10 minutes (30 minutes for tissues) at 4oC. The supernatant 
or clarified lysates were transferred to fresh microcentrifuge tubes. Total protein concentration in 
the lysates was determined using the BCA protein assay (Pierce BCA protein assay kit, Thermo 
Fisher Scientific) and normalized using the appropriate volume of lysis buffer. Lysates were 
diluted to achieve a final protein concentration of ~1.5mg/ml and 80 μl of the clarified lysate was 
mixed with 10 μl of activation mix [50 % Glycerol, 50 μM ATP, 60 mM MgCl2 0.05 % Brij35, 
0.25 mg/ml BSA] in a separate microcentrifuge tube and incubated on ice for 10 minutes. The 
mixture was then applied on the peptide arrays. After incubation at 37oC for two hours in a 
humidified chamber, arrays were washed with 1X PBST (1% Triton in 1X PBS) followed by 
staining with a phosphoprotein solution (Pro-Q Diamond Phosphoprotein Stain, Invitrogen) for an 
hour in the dark at room temperature. The arrays were then washed by gentle shaking for 10 min 
in a de-staining solution comprised of 20% acetonitrile and 50 mM sodium acetate, pH 4.0. The 
de-staining process was repeated three times. A final wash was performed with ddH2O and the 
arrays were air-dried (Figure 3.8).  
 
3.4.3 Signal detection and bioinformatics analyses 
 
            The processed arrays were then scanned using a GENEPIX professional 4200A microarray 
scanner at 532 to 560 nm with a 580 nm filter. The signal intensity corresponding to each 
phosphorylated peptide on the array was determined using the Genepix software, and the raw data 
were analyzed using the PIIKA 2 (Platform for Intelligent, Integrated Kinome Analysis) online 





Figure 3.8: Kinome analysis with peptide arrays. 
(A) Samples can represent cell lines, isolated cell types (like peripheral blood mononuclear cells) 
or tissues. (B) Cellular lysates are incubated on the array in the presence of ATP. (C) Arrays are 
either commercially purchased or generated through selection of peptides from online databases 
or phosphorylation site prediction software such as DAPPLE 2. (D) The signal from 
phosphostained or radio-labelled arrays are detected and quantified. (E) The output of the scanned 
arrays is analyzed by using software platforms such as PIIKA 2 or other approaches. (F) Results 
from kinome analysis are depicted in different formats such as heatmaps and principal component 
analysis (PCA) plots. (G) Biological events suggested through kinome analysis are typically 
validated through independent approaches such as functional assays or phosphorylation specific 
antibodies. (H) Finally, results from the validation can be used for various applications (Baharani 











3.4.3.1 Platform for Intelligent, Integrated Kinome Analysis (PIIKA 2) 
 
The array was printed with technical replicates and the analysis was completed using 
PIIKA 2 software (Maattanen et al., 2013b). This pipeline is specifically designed for the data 
collected from peptide arrays (Figure 3.9). The pipeline successfully handles the negative values, 
and without distorting the raw values, generates statistically significant outputs. The foreground 
and background mean values of each array were uploaded onto PIIKA 2. These values were 
utilized to perform statistical analyses and generate output files consisting of heatmaps, PCA plots, 
etc. After analyzing the outputs, I decided on the different validation strategies to be incorporated 
to determine the differential phosphorylation status of the peptides in the test sample (HD) versus 






Figure 3.9: Screenshot of the user interface of the PIIKA 2 web server.  
It involves five steps which includes uploading the file, the parameters for the analysis and the 












3.4.3.2 InnateDB  
 
            Next, step was to perform functional gene enrichment analyses using the InnateDB online 
tool to map the dysregulated phosphorylated targets to cognate signaling pathways. The details of 
the online web tool are described earlier in section 1.3.3.2. InnateDB mapped these targets to 
various canonical signaling pathways and a P ≤ 0.05 was used as a cut off for this analysis. Using 
phosphosite-specific information derived from PIIKA 2, InnateDB further classified these 
pathways as either upregulated or downregulated. Consequently, a list of the potentially up and 
down regulated pathways were shortlisted using the P-values for both NSC and R6/2 dataset 




Figure 3.10: Screenshot of the user interface of the InnateDB web server. 




3.5 SDS-PAGE  
 
            The independent validation of the significantly differentiated peptides; both in NSCs and 
murine study; based on the bioinformatics pipeline was performed by SDS-PAGE and Western 
blotting discussed in the following sections. Cell lysates (NSC) were prepared by first aspirating 
the media from the culture plates followed by gently rinsing the culture plates once with 1X PBS. 
The cells were then harvested using Axol neural unlock. This was followed by centrifuging to 
generate a pellet which was lysed in a freshly prepared RIPA lysis buffer (Table 3.4). The murine 
tissue (R6/2) samples were suspended in RIPA lysis buffer and sonicated with continuous 40 mA 
pulses for 3s five times on ice. Sonicated samples were centrifuged at 12,000 × g at 4°C for 30 
min and supernatant was collected for Western blot analysis. Protein samples were resolved via 
sodium dodecyl sulphate (SDS) Polyacrylamide gel electrophoresis (PAGE). SDS-PAGE was 
performed using the Mini-Protein 4 gel electrophoresis system (#165800FC, Bio-Rad, USA). 
Polyacrylamide gels (10%) with a 1.5 mm thickness were cast using the appropriate glass plates 
provided with the gel electrophoresis pack. The resolving gel comprised 10% acrylamide, 0.8% 
bis-acrylamide, 0.4% SDS, 375 mM Tris HCl pH 8.8, 0.16% (w/v) APS, 0.1% TEMED and H2O. 
The stacking gel comprised 4% acrylamide, 0.8% bis-acrylamide, 0.4% SDS, 125mM Tris HCL 
pH 6.8, 0.24% (w/v) APS, 0.1% (w/v) TEMED and H2O. The protein samples were boiled at 
100°C for 5 minutes prior to loading onto 10-well gels. The gels were run in 1x SDS running buffer 
at a constant voltage of 100 volts until the bromophenol blue dye front passed through the gel. 
 
3.5.1 Western Blotting 
 
            Gels were removed carefully from the glass plates after the electrophoresis. The stacking 
gels were discarded and the resolving gels were overlaid on a standard extra thick pre-cut filter 
paper (# 84783, Thermo Scientific) soaked in transfer buffer. Nitrocellulose membranes were cut 
to the size of the gel and soaked in transfer buffer then overlaid on the gels. This was covered with 
another pre-soaked standard extra thick filter paper and the entire assembly was placed in a gel 
holder cassette. The gel holder cassette was placed in the Western blotting electro blotting 
apparatus (Bio-Rad). This was filled with Western blotting 1x transfer buffer, pre cooled at 4°C. 
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Once the circuit was complete by attaching the lid, the protein transfer was run for 1.5 hours at 
100 volts at 4°C.  
 After the protein transfer was complete, the nitrocellulose membrane was removed from 
the cassette and placed in another container with 5% skim milk on a rocking platform and 
incubated for 40 minutes at room temperature. After blocking, the membrane was rinsed in 1x PBS 
to remove the residual skim milk followed by the addition of primary antibody buffer (Table 3.4). 
Primary antibodies were prepared at appropriate dilutions (listed below) and the membranes were 
soaked in the antibody buffer for overnight incubation at 4°C on a rocker. The membranes were 
washed with 1x PBST buffer 3x for 5 minutes each and then incubated with the appropriate 
secondary antibody (LICOR goat anti mouse/ goat anti rabbit, as mentioned below). Secondary 
antibodies were diluted in secondary antibody buffer (Table 3.4) at a concentration of 0.0001 
µg/mL and left at room temperature on a rocker for 1.5 hours. The membranes were washed 3x 
with 1x PBST (Table 3.3) for 10 minutes each and used for analysis on the LI-COR Odyssey 
infrared scanning instrument (LI-COR, USA). Image StudioTM Lite software (LI-COR, USA) 
linked to the LI-COR instrument was used to acquire the image at the appropriate laser intensities. 
The images acquired were transformed to grey scale and exported in the .jpeg and .tiff format for 
later use. The analysis was completed using the intensities estimated by the Image StudioTM Lite 
software. The expression of tubulin was obtained from the same blot as the primary antibody. The 
ratio of the both phospho and total protein over tubulin was used for normalizing. This was 
followed by a ratio of phospho over total protein to obtain a relative phosphorylation value for that 
particular protein and the comparative analysis was completed using t-test.  
 
3.5.2 Primary and secondary antibodies 
 
            Primary antibodies listed in Table 3.4 were purchased from Abcam, Cell Signaling 
Technologies (Danvers, USA), Thermo Fisher Scientific (Massachusetts, USA), Cedarlane 
(Ontario, Canada), and Sigma-Aldrich (Massachusetts, USA). Secondary antibodies for Western 
blotting, including IR Dye-680RD IgG (#926-68071), IR Dye-800CW IgG (#926-32211) and IR 
Dye-800CW IgG, (#926-32210) were purchased from Li-COR Odyssey (Nebraska, United 





Table 3.3: List of stock solutions of chemicals/reagents. Shown in in this Table is a list of stock 












Buffer/ Media Composition 
1x PBS (Phosphate 
buffered saline) 
137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM KH2PO4, 
pH 7.4. 
 
1x PBST 1x PBS, 0.1% Tween-20 (v/v) 
 
Blocking buffer 5% Skim milk in 1x PBS buffer (5 g Skim milk in 100 mL PBS 
buffer) 
 
Primary antibody buffer  0.1% Tween-20, 5% BSA in 1x PBS 
 
Secondary antibody buffer 0.1% Tween-20, 5% BSA in 1x PBS 
 
Western blotting Transfer 
buffer 
25 mM Tris, 192 mM glycine, pH 8.3, 20% methanol. 
1X SDS PAGE Running 
buffer 
25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3. 
 
RIPA lysis buffer 50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% Triton X-100 and 
0.5% sodium deoxycholate. Buffer supplemented with commercial 
protease and phosphatase inhibitor cocktails  
 
Peptide Array Buffer 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, 1 mM NaF, 1 μg/ml Leupeptin, 
1 μg/ml Aprotinin, 1 mM phenylmethylsulphonyl fluoride 
 
Refer to Table 3.1 for commercial source information 
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Table 3.4: List of primary antibodies used. Shown in this Table are the names, and working 
concentrations/dilutions of primary antibodies used in Western blotting. 
  
Primary Antibody  Working Concentration / Dilution 
  
Anti PAK1 + PAK2 + PAK3 (CST 2604) 1:1000 
Anti-AKT (CST 2938S) 1:1000 
Anti-Cdk2 (ab 32147) 100 µl at 0.128 mg/ml / 1:1000 
Anti-Cofilin (CST 3313S) 1:1000 
Anti-LIMK1 Abcam (ab 95186) 100 µl at 0.2 mg/ml / 1:1000 
Anti-MAKPAPK2 (CST 9329S) 1:1000 
Anti-p38 (ab170099) 100 µl at 0.273 - 0.288 mg/ml / 1:1000 
Anti-Profilin 1 (CST 3237) 1:1000 
Anti-PTEN Abcam (ab 31392) 100 µg at 1 mg/ml / 1:1000 
Anti-ROCK2 (CST 8236) 1:1000 
Anti-Slingshot (Cedarlane SK6410) 1:500 
Anti-TAB1 (ab 76412) 1:1000 
Anti-ULK1 (CST 6888) 1:1000 
Phospho AKT1 (CST 9018S) 1:500 
Phospho Cdk2 (ab 194868) 100 µl at 1.14 - 2.34 mg/ml / 1:500 
Phospho Cofilin, (CST 5175S) 1:500 
Phospho LIMK1 (ab 38508) 100 µg at 1 mg/ml / 1:500 
Phospho p38 (ab 60999) 100 µg at 1 mg/ml / 1:500 
Phospho PAK (ab 2477) 100 µg at 1.94 mg/ml / 1:1000 
Phospho Profilin 1 (ab 215752) 1:1000 
Phospho PTEN (ab 131107) 1:1000 
Phospho ROCK2 (ab 228008) 100 µl at 0.13 mg/ml / 1:1000 
Phospho TAB1 (Thermo PA5-12851) 1:500 
Phospho ULK1(CST 8054S) 1:500 
α-Tubulin  (ab4074) 1 µg/ml  / 1:20,000 






            The validation of the significantly differentiated peptides was completed by Western 
blotting using commercial antibodies. This was used to validate a single pathway proposed to be 
dysregulated in the disease. There were many other peptides in the NSC and murine output that 
could be validated but instead I took a high throughput approach. This allowed to summarize the 
results utilizing an online tool (NetworKIIN) that predicts the upstream kinases that regulate the 
significantly phosphorylated peptides on the array. 
          NetworKIN (Version 3.0) platform was used to identify candidate kinases upstream of the 
phosphosites identified in our kinome analyses (Figure 3.11). The NetworKIN tool predicts the 
kinase substrate relationship (Linding et al., 2008). The tool integrates information on various 
kinase-specific and phospho-binding domain-specific motifs derived from the NetPhorest database 
and uses STRING to improve the prediction of cellular kinase-substrate relationships (Linding et 
al., 2008) (Miller et al., 2008).   
          Significantly dysregulated (hyper-phosphorylated or hypo- phosphorylated phosphosites 
were used to predict upstream kinases using the NetworKIN tool 
(http://networkin.info/index.shtml) (Version3.0) (Linding et al., 2008). The original list was 
divided into two separate list and then uploaded individually on the NetworKIN online tool as 
hyper and hypo phosphorylated peptides. The resulting predicted annotations were filtered using 
a NetworKIN confidence score cut-off of 3.0 for the cell lines dataset and a NetworKIN score-
difference cut-off of 4.0 for the mouse dataset. Since the mouse dataset comprised of 1268 unique 
peptides and the cell line 298 a higher cut off was used for it. The score-difference defined the 
maximum difference between the best prediction and the second-best prediction.  The results can 
be downloaded in an excel format from the web. The identified kinases for both, hyper- and hypo-
phosphorylated phosphosites were plotted on a mammalian kinase-dendrogram, for visual 






Figure 3.11: Screenshot of the user interface of the NetworKIN web server. 
The input files are uploaded and the score-difference cut-off is defined. The results can be 











            The predicted kinases based on the NetworKIN online tool were mapped on a “kinome 
tree”, the details of which are described here. KinMap (http://kinhub.org/kinmap/) is a web-based 
tool to map kinases based on the kinome data. The software is built on the availability of a dataset 
that links them to the upstream kinases (Figure 3.12). The knowledge of the structural, 
biochemical, functional and disease association of a kinase is utilized to predict the upstream 
kinases. This platform facilitates a visual representation of the predicted kinases and represents 
such data on a kinome tree. The sophisticated kinome tree annotations also allow a comparison of 
the kinases between sexes, disease progression states, etc.; thus, providing more options for 
therapeutic interventions. KinMap supports multiple input and output formats and can recognizes 
alternate kinase names thus making it extremely user-friendly. The names of the kinases can be 
manually inputted or uploaded on the web server. There are different symbols which can be color 
coded and used to represent the kinase. The size of the symbols can indicate their significance. 
These high quality pictures can be downloaded after submitting the data in different image formats.  
 
Eight different families of enzymes (Figure 3.13) can be represented on the kinome tree, including: 
 
1. AGC - Containing PKA, PKG, PKC families 
2. CK - Cell/Casein Kinase  
3. STE - Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases  
4. TKL - Tyrosine kinase–like - TKL 
5. TK - Tyrosine kinase  
6. CMGC- Containing CDK, MAPK, GSK3, CLK families  
7. CAMK - Calcium/calmodulin dependent protein kinase - CAMK 







Figure 3.12: Screenshot of the user interface of the KinMap web server. 
The input file can be uploaded manually or imported from an excel format and after submission 
the kinases are represented on the kinome tree. The annotated image of the human kinome tree can 






Figure 3.13: Graphic representation of the kinome tree with all families. 
[Containing PKA, PKG, PKC families 2 (AGC), Cell/Casein Kinase (CK), Homologs of yeast 
Sterile 7, Sterile 11, Sterile 20 kinases (STE), Tyrosine kinase–like (TKL), Tyrosine kinase (TK), 
Containing CDK, MAPK, GSK3, CLK families (CMGC), Calcium/calmodulin dependent protein 












            The results discussed in this section have been generated by a mix of both experimental 
and bioinformatics analyses. For ease of explanation, Figure 4.1 outlines the different 
bioinformatics tools that were used to generate and validate the experimental data. The blue 
(input), light green (output) and dark green represent the bioinformatics tools used for the analysis 
of the experimental data. The red indicates the peptide array experiments using cell / tissue lysates, 
followed by validation using Western blotting.  
 
4.1 Human neural stem cells 
 
            A previously designed peptide array comprising 298 unique peptides that represented well-
characterized signaling proteins implicated in cell survival, proliferation, motility, and immune 
response-related pathways was used for kinome analysis (Arsenault et al., 2012a). This array was 
used as a platform to screen for potential signaling differences in NSCs derived from an HD 
patient. As a biological control, HC NSCs were utilized. To ensure reproducibility and statistical 
rigor, arrays were designed to include a total of nine replicates of each unique peptide (Jalal et al., 
2009; Li et al., 2012).  Overall, our analyses led to the identification of a total of 128 peptides that 
demonstrated significant differences (P < 0.1) in their levels of phosphorylation between the HD 
and HC NSCs. Fifty-two of these differentially phosphorylated peptides were hyper-
phosphorylated in HD compared to HC, while 76 were found to be hypo-phosphorylated. A 
peptide was selected for further analysis if its P-value was ≤0.1 with a fold change of ± > 1 (Li et 
al., 2012; Maattanen et al., 2013a; Maattanen et al., 2013b). This liberal threshold allowed to 
reduce the possibility of losing potential phosphorylated events while performing pathway 
analysis. Finally, the priority of kinome analysis is to identify biological events that are 
subsequently validated through independent approaches. This increases the likelihood of 
identifying kinases that are dysregulated based on significantly differentially phosphorylated 
peptides in the HD NSCs. The list of up- and down-regulated peptides along with their fold 






Figure 4.1: Experimental outline.  
The flowchart outlines the general pipeline for the peptide array analysis, up to the validation step. 
The PIIKA outputs are divided into two where one follows the validation experiments (left) and 
the other follows the bioinformatics pipeline (right) used to predict the upstream kinases that are 
dysregulated in the disease process. Blue and green represents the online software tools utilized 
for the experiments. Red indicates the experiments performed to generate the data followed by 
validation. PTM here refers to phosphorylation events. 
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            The next step was the functional gene enrichment analyses using the InnateDB tool to map 
the dysregulated phosphorylated targets to cognate signaling pathways. InnateDB mapped these 
targets to 24 canonical signaling pathways (P ≤ 0.05). Using phosphosite-specific information 
derived from PIIKA 2, InnateDB further classified these pathways as either upregulated or 
downregulated (Breuer et al., 2013). Consequently, four pathways as potentially upregulated and 
20 pathways as potentially downregulated were identified (Table 4.1 and 4.2). The InnateDB 
output is presented in five columns for simplicity, as shown in the Tables below, which represents 
the pathway name followed by ID and the database that provided the information under the column 
source name which is followed by P-value and finally gene names involved in the pathway. 
InnateDB integrates information from a variety of external resources (PID, NID, KEGG etc.) 
thereby, supplementing its own curated interactions (Breuer et al., 2013). Such factors make it 
necessary to broaden the search and carefully compare the outputs of both PIIKA 2 and InnateDB 
to identify common peptides that were significantly differentially phosphorylated for further 
validation by Western blotting (Table 4.3).  
            A number of pathways were listed in the output from InnateDB such as p53 mediated 
signaling, caspase cascade etc. The peptides dysregulated in the cytoskeletal pathway were the 
most prominent based on PIIKA 2, InnateDB and Neurolucida results, discussed later. The 
peptides selected for validation by Western blotting were LIMK1 and cofilin which are shown in 















Table 4.1: List of up regulated pathways in NSCs along with the P-values (<0.05) based on 
InnateDB pathway analysis.  
 
Pathway Name Pathway ID Source Name  P-value Gene Symbols 
Il12 and STAT4 
dependent signaling 




0.01 MAPK14, STAT4  
p53 pathway 15289 PID NCI 0.03 AKT1, CDK2, 
MAPK14, MDM2, 
PPP2CA, TP53  
p53 signaling 
pathway 
597 KEGG 0.05 BAX, CASP3, 
CDK1, CDK2, 
MDM2, PTEN, 
TP53   














Table 4.2: List of down regulated pathways in NSCs along with the P-values based on 
InnateDB pathway analysis.  
 
Pathway Name Pathway ID Source Name  P-value Gene Symbols 
Caspase Cascade in 
Apoptosis 







15876 PID NCI 0.02 CASP3, CTNNB1, 













18658 REACTOME 0.03 CASP3, XIAP   









0.03 ACTA1, FYN   
M-calpain and 




0.03 ACTA1, EGFR   
Nephrin/Neph1 
signaling in the 
kidney podocyte 
14899 PID NCI 0.03 AKT1, FYN   
Phagosome 10394 KEGG 0.03 EEA1, NCF1  
SMAC binds to 
IAPs  
13396 REACTOME 0.03 CASP3, XIAP  
SMAC-mediated 
apoptotic response 
17242 REACTOME 0.03 CASP3, XIAP  
SMAC-mediated 
dissociation of IAP: 
caspase complexes  








15336 PID NCI 0.03 EGFR, FYN   
Thromboxane A2 
receptor signaling 
14941 PID NCI 0.03 AKT1,  EGFR  
Viral myocarditis 8123 KEGG 0.03 CASP3, FYN  
Follicle stimulating 
hormone 
15929 NETPATH 0.03 AKT1, CREB1, 
EGFR, EIF4EBP1,  
FYN,  MAPK14, 






4359 KEGG 0.03 AKT1, CDC42, 
LIMK1, NCF1, 
PIK3R1, PIK3R2, 
PLCG2, RPS6KB1  
Alpha6Beta4Integrin 15905 NETPATH 0.06 AKT1, CASP3, 
EGFR, EIF4EBP1,  








0.06 AKT1, CASP3, 
CHUK, CTNNB1, 
EGFR,  IKBKB , 
PDPK1, PIK3R1, 
RELA   
 
 
4.1.1 Validation of peptide array targets 
 
            The most prominent pathway that appeared to be dysregulated was the cytoskeleton 
represented by LIMK1 and cofilin on the peptide array. LIMK1 is the kinase that phosphorylates 
cofilin and phosphatase Slingshot dephosphorylates it. All the peptides were validated by Western 
blotting as shown below. It is more suitable to measure phosphorylation vs. the total expression of 
a protein, the ratio (relative phosphorylation) which was used to represent the difference between 
HC and HD (Bass et al., 2017).  
 
 
Table 4.3: List of peptides validated by Western blotting. Shown in this table are the names of 
the peptide followed by their P-values and fold change obtained from kinome analysis. The 
primary antibodies used were against the phosphosites, mentioned in the table.   
 
Name ID Target P-value Fold change      
Cofilin 1  P23528 S3 0.050 -1.71 
LIMK1  P53667 T508 0.019 -1.56 




4.1.1.1 Cytoskeletal Dynamics – LIMK1, Cofilin, SSH1L  
            LIMK1-T508 and cofilin-S3 were hypo-phosphorylated in the HD NSCs, thereby 
suggesting a third regulator, the phosphatase Slingshot (SSH1L) - in the actin cytoskeletal 
dynamics in HD NSCs (Figure 4.2A). The regulation of actin microfilaments found in neurons and 
their specific concentrations in the synaptic terminals, dendritic spines, and growth cones (Figure 
1.8) (Fifkova and Delay, 1982) makes this trio (LIMK1-cofilin-SSH1L) an important regulator for 
the maintenance of the actin cytoskeleton (Figure 4.2B). Essential aspects of synaptic plasticity, 
neuronal morphology, and motility in the cell cycle in response to extracellular signals have all 
been associated with dynamic remodeling of actin monomers (dos Remedios et al., 2003). Cofilin 
is inactivated by LIM kinase (LIMK)-mediated phosphorylation, which inhibits its interactions 
with actin filaments and actin monomers (Dawe et al., 2003; Yang et al., 1998) . Its reactivation 
occurs through dephosphorylation by SSH1L-S978 (Niwa et al., 2002). Cofilin is directly involved 
in actin dynamics and its hyper-phosphorylation leads to disintegration of the cytoskeletal structure 
of actin filaments (Wioland et al., 2017).  
            The results obtained from the NSCs cannot be considered confirmatory since they are from 
a single sample. The results suggest that the hypo-phosphorylation of LIMK1 upstream of cofilin 
did not correlate with its function as a kinase phosphorylating cofilin. Another upstream regulator 
of cofilin is a SSH1L, which is a cofilin-S3-specific phosphatase that drives the negative feedback 
inhibition of LIMK1-mediated cofilin-S3 phosphorylation (Yang et al., 1998). Here, both LIMK1 
and SSH1L show reduced phosphorylation suggesting that they are in an inactive and active state 
respectively. Cofilin is hyperphosphorylated indicating that the kinase is active or the phosphatase 
is inactive. These results indicated a more complex mechanism for the contributions of SSH1L-
LIMK1 in the regulation of cofilin. A previous study established that SSH1L and LIMK1 form a 
complex that leads to the dephosphorylation of LIMK1 and inhibition of its kinase activity 
(Soosairajah et al., 2005). Furthermore, there might be crosstalk between the proteins of signaling 
cascades as both LIMK and Slingshot have isoforms. Profilin also affects the actin polymerization 
and depolymerization due to its interactions with cofilin (Minamide et al., 2000; Wioland et al., 
2017). These results might not exactly corroborate the biology however they suggest that there is 
dysregulation in the phosphorylation status of the cytoskeletal proteins thus affecting actin 
dynamics. Further validation using different biological samples from patients might be able to 





Figure 4.2A: Western blot analysis of phosphoproteins indicated the activation of 
cytoskeletal signalling pathways. 
Representative blots along with the ratio of the phospho (p) to total (t) (relative phosphorylation) 
cofilin-S3, LIMK1-T508 and SSH1L-S978 in this study. Quantification of Western blot band 
intensities of the selected phosphorylated proteins and their respective total proteins were 





Figure 4.2B: Schematic of actin polymerization and depolymerization. 
The kinase LIMK phosphorylates cofilin rendering it inactive leading to actin polymerization. The 
phosphatase slingshot activates cofilin by removing the phosphate. Both LIMK and Slingshot have 









            After validating the peptide array targets for cytoskeletal pathway by Western blotting, I 
set out to determine the upstream kinases that regulated these significantly differentially 
phosphorylated peptides. To do this I used a bioinformatics online tool, NetworKIN 
(http://networkin.info/index.shtml), which allows systematic matching of kinases to specific 
motifs. This greatly enhances the motif predictions and exploring cellular phosphorylation 
networks (Linding et al., 2008). NetworKIN allows 60-80% prediction capability for in silico 
analyses, thus, increasing the probability of an accurate identification of a kinase responsible for a 
particular phosphorylation event (Linding et al., 2008). NetworKIN analyses of significant 
upregulated peptides with a score of >3 resulted in 21 candidate kinases (Supplementary Table 
S3). The score-difference defined the maximum difference between the best prediction and the 
second-best prediction. These kinases are predicted to play a significant role in the progression of 
the disease process and can be explored as therapeutic targets. Kinases targeting multiple phospho 
sites were CK2α (3 phosphosites, NetworKIN score range: 10.59 - 35.64), GSK3β (3 phosphosites, 
NetworKIN score range: 6.17 – 9.20), GSK3α (2 phosphosites, NetworKIN score range: 3.73 – 
6.08), IKKα (2 phosphosites, NetworKIN score range: 17.18 – 17.33), JAK2 (2 phosphosites, 
NetworKIN score range: 3.41 – 8.07), MAP2K6 (2 phosphosites, NetworKIN score: 16.27), 
MAPK11 (2 phosphosites, NetworKIN score range: 8.71 – 13.04), MAPK8 (2 phosphosites, 
NetworKIN score range: 7.90 – 9.54), PKAα (2 phosphosites, NetworKIN score: 5.88), PKAβ (2 
phosphosites, NetworKIN score range: 8.64 – 8.65), PKAγ (2 phosphosites, NetworKIN score 
range: 8.64 – 8.65), Tyk2 (2 phosphosites, NetworKIN score range: 7.88 – 8.0). Similarly, the 
NetworKIN analyses of downregulated peptides with a score of >3 corresponded to 21 candidate 
kinases. Kinases with multiple phospho sites were PDHK1 (6 phosphosites, NetworKIN score 
range: 3.17 – 60.25), MAPK1 (4 phosphosites, NetworKIN score range: 5.97 – 31.24), PKBα 
(AKT1) (3 phosphosites, NetworKIN score range: 5.08 – 15.59), HIPK2 (3 phosphosites, 
NetworKIN score range: 3.30 – 4.27), Kit (2 phosphosites, NetworKIN score range: 29.90 – 
30.11), MAPK11 (2 phosphosites, NetworKIN score: 5.82), MAPK3 (2 phosphosites, NetworKIN 
score range: 7.62 – 14.74), TRKA (2 phosphosites, NetworKIN score range: 24.44 – 24.35). Based 
on the analyses by NetworKIN, I sought to determine whether the WB analyses for one of the 
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predicted kinases, GSK3β, and its upstream kinase, MK2, shows a difference in their 
phosphorylation status using phospho-specific antibodies.  
 
4.1.2.1 GSK3β and MK2 
 
            The analysis of the hyper phosphorylated peptide by kinome analyses and investigation by 
the NetworKIN platform predicted GSK3β as one of the upstream kinases dysregulated in HD 
which is implicated in cytoskeletal changes (Figure 4.3A). An upstream regulator of GSK3β is 
MK2, which has been implicated in the microtubule dynamics (Yuan et al., 2010) was also 
investigated by WB (Figure 4.3B). Glycogen synthase kinase-3 is a serine/threonine protein kinase 
that is highly expressed in the brain. Phosphorylation of GSK3β at S9 renders it inactive (Beurel 
et al., 2015) and its abnormal phosphorylation of the microtubule-binding protein, tau, is suspected 
as a primary event in the formation of the neurofibrillary tangles in Alzheimer's disease brains 
(Mandelkow et al., 1992). It is interesting to note similar dysfunctionalities are observed in the 
HD NSCs, a neurodegenerative disorder. Kobayashi et al. showed that the activation of LIMK1 
by MK2 induces cell migration (Kobayashi et al., 2006). When phosphorylated at S9, GSK3β is 
enzymatically inactive and more likely to be degraded, whereas the phosphorylation of MK2 at 
T222 and T334 (by stress-activated kinases such as p38α) induces MK2 enzymatic activity (Yuan 
et al., 2010) (Figure 4.5B). The WB results indicated that the expression level of phosphorylated 
GSK3β (S9) and MK2 (T222-p1 and T334-p2) were concurrently increased, suggesting the 
inactivation of GSK3β which ultimately could contribute to the dysregulation of microtubule 
dynamics. The biological signaling can be confirmed with an increase in the sample size. The 
results depicted in Figure 4.3A are and not absolute but suggestive of a biological function, as they 












Figure 4.3A: Western blot analysis of phosphoproteins confirmed the activation of specific 
intracellular signalling pathways revealed by NetworKIN and its upstream kinase. 
Representative blots along with the ratio of the phospho (p) to total (t) GSK3β-S9 as an output of 
in silico analysis based on the peptide array dataset. Western blot analysis of MK2 upstream of 
GSK3β with the ratio of the phospho (p) to total (t) MK2 (p1-T222, p2-T334). Quantification of 
Western blot band intensities of the selected phosphorylated kinases and their respective total 













Figure 4.3B: Schematic representing the microtubule stability.  
Phosphorylation of GSK3β at S9 renders it inactive and its abnormal phosphorylation of the 
microtubule-binding protein. It is regulated by the upstream kinase MK2 which is a downstream 









            A dendrogram of the human kinome was constructed using KinMap (Eid et al., 2017). It 
highlighted the candidate kinases predicted to target the significantly differentially phosphorylated 
peptides on the array. The identified kinases for both, hyper- and hypo-phosphorylated 
phosphosites were uploaded on NetworKIN (Linding et al., 2008), which predicted the kinases 
phosphorylating those peptides. The candidate kinases identified by NetworKIN analysis were 
selected based on a cut-off score of 10 and represented on the mammalian kinase-dendrogram, using 
the KinMapbeta online tool. The NSCs were obtained from a female patient, and hence, a circle was 
used to represent the dataset. The upregulated kinases were represented in red and downregulated 
in green. This is a simple visualization of a compound profiling dataset, which allowed us to 
answer complex questions pertaining to the involvement of the kinases in the disease. The in-depth 
analysis of these outputs also enables the identification of new avenues for kinases in drug 
development projects. 
        The dendrogram shows a wide distribution of the predicted kinases across different families, 
but the largest node size is seen on Atypical Protein Kinases (APK), whose functions are largely 
unknown (Manning et al., 2002). The node size is proportional to the number of phosphosite 
targets of the kinases. In this study, two prominent APKs were predicted (black arrows, Figure 
4.4), including ATM (Serine/threonine protein kinase ATM) (green) and PDHK1 (Pyruvate 
dehydrogenase (acetyl-transferring)] kinase isozyme 1) (red). Both play an important role by being 
activated during stress and apoptosis. ATM activates during DNA damage specifically checkpoint 
signaling upon double strand breaks (DSBs), whereas PDHK1 during mitochondrial dysfunction  
and protects the cells against apoptosis in response to hypoxia and oxidative stress (Barone et al., 










Figure 4.4: Dendrogram of the human kinome generated using KinMap predicts the kinases 
involved HD NSCs. 
Dendrogram of the human kinome constructed using KinMap (Eid et al., 2017), highlighting the 
candidate kinases predicted to target the upregulated and downregulated phosphosites in HD 
NSCs. Candidate kinases were identified by NetworKIN (Linding et al., 2007) analysis.  Node 
size is proportional to the number of the phosphosites targeted by the kinase.  All major kinase 
families are annotated in the dendrogram and include: TK (Tyrosine Kinases), TKL (Tyrosine 
Kinase-Like), STE (Sterile kinases; homologs of the yeast STE7, STE11 and STE20 kinases), CK1 
(Casein Kinase 1), AGC (comprising Protein kinase A/ PKA, PKG and PKC kinase sub-families), 
CAMK (Calcium/Calmodulin-dependent kinases) and CMGC (comprising cyclin-dependent 
kinase (CDK), mitogen-activated protein kinase (MAPK), glycogen synthase kinase (GSK) and 
CDC-like kinase (CLK) and APK (Atypical Protein Kinases). 
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4.1.4 Neurolucida 360 
 
            Results from our kinome and WB analyses suggested that cofilin, LIMK1 and SSH1L were 
altered in HD NSCs (Figure 4.2). A correlation between LIMK inactivation and altered 
cytoskeletal dynamics has been observed (DiProspero et al., 2004; Narayanan et al., 2016), which 
affects the neurite morphology (Sainath and Gallo, 2015). Actin microfilaments have specific 
locations in the neurons and are particularly concentrated at the synaptic terminals, dendritic spines 
and growth cones (Gordon-Weeks, 1987; Matus et al., 1982) (Figure 1.8). Neurons are polarized 
cells, and thus, rely on a strong cytoskeletal network to maintain the typical neuronal morphology 
that allows the proper functioning of the neuron and neuronal plasticity. Abnormal signal 
transduction could impact the cytoskeleton negatively and affect actin microtubule dynamics. 
Therefore, to determine whether dysregulated cofilin, LIMK1 and SSH1L in HD-derived NSCs 
could lead to altered neurite outgrowth an artificial reconstruction of the neuronal structure was 
completed. Neurolucida 360 platform (Dickstein et al., 2016), accurately traced and reconstructed 
intricate neuronal structures and quantitatively assessed the neuronal soma and neurite length 
associated with HD and normal NSCs. With this automatic neuron construction tool, one could 
completely reconstruct neurons and its complex network of dendrites, axons, etc., and using the 
detection algorithm, analyze the length of these extensions and the number of soma (cell bodies). 
This facilitated comparisons of the disease conditions to the control, providing a visual, numerical 
and analytical assessment of the disease progression. The results from six fields demonstrated a 
significant difference in neurite length between the HD and HC NSCs (Figure 4.5). The average 
neurite length of HD NSCs was found to be up to 25% shorter than the average neurite length of 
HC NSCs (P < 0.002). No significant difference was observed in the density and soma size between 
the corresponding NSCs, thus suggesting that about the same number of somas resulted in a sparser 
network of neurite branching in HD, compared to HC NSCs. Collectively, the data suggests that 
abnormal functioning of LIMK1, cofilin and SSH1L in HD-derived NSCs potentially leads to 
perturbed cytoskeletal dynamics in those cells and that this could predispose to poor neurite 
outgrowth in HD pathogenesis and eventually, to a loss of synaptic integrity. 





Figure 4.5: Neurolucida tracings of neurons in the HC and HD NSCs 
 (A) Representative image of HC and HD NSCs by averaging six fields. The indicated cell lines 
were cultured to approximately 80% confluence and phase-contrast images of the cells were 
acquired at 20x magnification using a light microscope. (B) Reconstruction of the neurite 
extensions were generated using Neurolucida 360 and the representative overlay indicating the 
soma and neurite extensions are shown here. (C) Reconstruction of the soma and cell body with 
the scale bar measuring 100μm. (D) Reconstruction was used for quantitative analyses of the total 
neurite length of six HC and HD images. (E) Quantification of the neuronal morphology in HD 
and HC NSCs. (F) Results from the analysis of mean soma lengths in both HD and HC NSCs. Bar 
graph shows mean ± standard deviation , **P < 0.005, n = 6 experiments, unpaired t-test. HC = 







4.1.5 Discussion  
            
            Herein, NSCs and R6/2 HD mice were used as a model to study the signaling aberrations 
underlying HD pathogenesis. Specifically, kinome analysis was applied to NSCs derived from the 
fibroblasts of a female HD patient with a clinically-diagnosed symptomatic age of onset of 48 
years. This phosphorylation (peptide array) platform and kinome analysis represents a cost-
effective and powerful high-throughput approach to probe for cognate and disease-specific 
kinases. Several models, including immortalized neuronal cell lines and transgenic mouse models, 
have been used to study HD pathology (Cisbani and Cicchetti, 2012; Ferrante, 2009). These 
models have provided critical information regarding HD pathogenesis, and are somewhat able to 
recapitulate the underlying molecular characteristics displayed in the HD patient brain and are an 
invaluable resource to allow for modelling disease pathologies.  
            Several recent studies have reported the dysregulation of cytoskeletal dynamics in 
neurodegenerative disorders, although the molecular mechanisms by which they occur are not 
always apparent (Goldberg, 2003; Guo et al., 2014b; Heng et al., 2010; Niwa et al., 2002). LIM 
kinases are known to play a role in cytoskeletal dynamics (Briz and Baudry, 2014; Endo et al., 
2007). The LIMK family includes LIMK1, which is highly expressed in the brain, and LIMK2, 
which is ubiquitously expressed throughout the body (Proschel et al., 1995; Takahashi et al., 
1998). These kinases are downstream effectors of Rho-GTPases and regulate the actin 
cytoskeleton architecture (Proschel et al., 1995). Upregulation of LIMK1 increases axonal growth 
while its downregulation causes the opposite effect (Heng et al., 2010; Koch et al., 2014). The 
phosphorylation of LIMK1-T508 increases its activity and is associated with enhanced LIMK1-
dependent regulation of actin cytoskeletal dynamics (Cuberos et al., 2015; Petrilli et al., 2014). 
LIMK1 is known to directly phosphorylate cofilin on S3, which inactivates cofilin and prevents 
its binding to actin (Yang et al., 1998). In contrast, Slingshot phosphatase-1 also targets S3, and 
promotes cofilin (re)activation (Romarowski et al., 2015). Loss of cofilin function due to 
phosphorylation at S3 impairs monomeric actin-turnover (G-actin) in the cytoplasm, leading to 
morphological deficits, as demonstrated in Figure 4.2B (Munsie et al., 2012). The impairment of 
G-actin affects profilin that balances the F/G actin ratio which ultimately affects the actin 
polymerization (Posey et al., 2018). 
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            This study revealed hypo-phosphorylation of LIMK1 T508 in HD NSCs, but an increase 
in cofilin S3 phosphorylation. Hypo-phosphorylation of SSH1L was at S978, reduces its 
phosphatase activity and suggested the existence of a complex interplay of LIMK1-cofilin-SSH1L 
pathway. Such phosphorylation also likely contributes to the loss of actin integrity in HD as 
observed in other neurodegenerative diseases, including Alzheimer disease (Bamburg and 
Bernstein, 2016; Barone et al., 2014). It is well established that the calcium levels in HD brains 
are elevated and contribute to cellular toxicity and death (Cheng et al., 2003; Raymond, 2017; 
Wang et al., 2005). Therefore, it is possible neuronal actin cytoskeletal dynamics and organization 
may be dependent on Ca2+ calcineurin - induced SSH1L activation and cofilin deactivation (Wang 
et al., 2005). Another mechanism for dysregulation of SSH1L is the ROS- (Reactive oxygen 
species) dependent activation of the SSH1L-cofilin pathway which stimulates the SSH1L-
dependent formation of cofilin-actin rods; therefore, affecting the actin dynamics (Kim et al., 
2009). All living cells generate ROS, which at a moderate concentration, play important 
physiological roles, but at high levels generate oxidative stress to which the central nervous system 
(CNS) is particularly vulnerable. Neurodegenerative disorders (NDD) are late-onset and prone to 
oxidative stress. Misfolded proteins accumulate as a result of stress and these proteins are 
vulnerable to modification by the carbonyl products of oxidative stress (Kim et al., 2015; Liu et 
al., 2017).  
  Overall, the neuronal tracings, kinome analysis and bioinformatics prediction suggest, 
among other things, differences in microtubule assembly (Figures 4.2-4.5) and the findings present 
evidence that cofilin dysregulation via SSH1L/LIMK1 inactivation is a potential molecular 
hallmark of HD pathology. NetworKIN predicted GSK3β, ATM and PDHK1 as one of the major 
upstream kinases, potentially activated in HD NSCs. These results suggest a complex interplay 
between the cytoskeletal proteins and its upstream kinases. The sample size was one hence it 
cannot be definitively suggested whether stress or DNA damage causes the dysregulated kinase 








4.2 R6/2 Huntington mouse studies 
 
            Alteration in the kinase signaling has been verified in various cellular and mouse models 
over the years in HD. R6/2 is a progressive mouse model of the disease, and hence, subtle changes 
in the disease process can be well documented. The onset of HD pathology in humans is generally 
triggered in their mid-40’s, although it is known that the patients are born with the defective gene. 
This clearly suggests that the fate of HD patients is sealed by birth. How signaling is altered in the 
early stages of life is not clearly understood and leads to the question of whether these pathological 
defects affect neural development. This study focused on answering some of these questions by 
comparing global kinase signaling of HD and HC across major neural developmental time points 
using R6/2 mice. This was accomplished using whole brains for the embryonic time points. To 
understand the signaling defects in the other significant developmental milestones, striatal tissue 
was selected for the analysis which is the most affected in HD. These time points captured the 
various physiological changes in the disease process to study the biochemical changes due to 
(de)phosphorylation by the kinases, and the causes thereof.   
 
4.2.1 Validation of peptide array targets 
 
            As discussed previously, I designed a custom 1268 peptide array (Supplementary Table 
S4) that represented signaling proteins implicated in cell-survival, proliferation, neural-
development, cytoskeleton, energy metabolism, transcription and immune-related pathways. This 
array was used as the platform to screen for potential signaling differences in the neural tissue 
derived from age and sex matched R6/2 murine model of HD. Based on the peptide array and 
pathway analysis results there were five pathways that appeared to be significantly affected across 
the eight time points. They were i) Cytoskeletal dynamics; ii) Calcium signaling; iii) Transcription; 
iv) Cell cycle regulation; and v) Energy Metabolism. I selected significant peptides involved in 
cytoskeletal dynamics to validate by Western blotting as this pathway was also significantly 
affected in the human NSCs. This allowed a better understanding of the defective kinase signaling 
(kinome analysis) across significant developmental time points that lead to the disease symptoms 




4.2.1.1 Cytoskeletal dynamics 
 
            The priority of kinome analysis is to identify targets that are validated by independent 
approaches, which in this case was Western blotting. In both cases the direct measurement is the 
extent of phosphorylation in the peptide / protein (array / WB). The distinction is that this study is 
attempting to capture the phosphorylation status of a peptide in vitro (array), and compare it to the 
phosphorylated protein in vivo (cell/tissue).  
As discussed previously, the peptide was selected from the PIIKA 2 output for further 
analysis with a P <0.2 and a fold change of > ±1 (Goel et al., 2018; Maattanen et al., 2013a; 
Maattanen et al., 2013b) (Supplementary Table S5). This liberal threshold allowed us to avoid 
false positives while performing pathway analysis. As described earlier, the InnateDB tool was 
used to map the dysregulated phosphorylated targets to multiple cognate signaling pathways. 
Using phosphosite-specific information derived from PIIKA 2, these pathways were classified as 
upregulated or downregulated (i.e., positive fold change as up and negative as downregulated). 
This dataset was uploaded for pathway analysis to the InnateDB online tool and consequently this 
analysis identified different signaling pathways that were dysregulated across the different time 
points in the disease process (Supplementary Tables S6 and S7). In this case I had to verify that 
the significantly phosphorylated peptides selected were based on their differential phosphorylation 
status across time points, which meant that a peptide should have a significant change in its 
phosphorylation across at least half of the time points (4 out of 8). Overall, this analyses led to the 
identification of cytoskeletal signaling as the major dysregulated pathway in HD R6/2 neural 
tissues. Figure 4.6 shows the peptides that were validated by Western blot analysis, while Table 








Figure 4.6: Molecular signaling involved in cytoskeletal organization. 
This map illustrates the Rho kinase signaling pathway, the key effectors, and its downstream 
targets that ultimately affect actin polymerization. The molecules represented in pink and grey are 
kinases while profilin and cofilin have no such activity. Activation of ROCK and PAK lead to the 
phosphorylation and activation of LIMK thus allowing the phosphorylation of cofilin which leads 
to its deactivation. It’s reactivated by the phosphatase SSH1L shown here in green. SSH1L is 
modified by multiple upstream regulators such as PI3K, ROS, calcium etc. Profilin (orange) and 
cofilin (yellow) are involved in maintaining the balance between F and G actin which regulates 
actin polymerization.  * Represents the peptides that were selected for validation based on their 
significant differential phosphorylation in the peptide array. ROCK1=Rho associated protein 
kinase 1, PAK=p21 activated kinase, LIMK1=Lim domain kinase, SSH1L=slingshot phosphatase, 
ROS=Reactive oxygen species. G=globular, F=Filamentous, Ca+2 =Calcium, ROS=Reactive 
oxygen species.  
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Table 4.4: List of peptides selected for validation based on PIIKA 2 output with fold changes 
and P-values for every time point and both sexes [male (M) and female (F)]. The bold represent 
the time points with significant P-values. E = embryonic, P0 = at birth, w = week. 
 
Name ID Target Time point Fold change P-value 
ROCK2 P70336 S1366  E9_F   1.41  0.02 
       E9_M   1.04  0.41 
       E14_F - 1.09  0.31 
       E14_M   1.31  0.08 
       P0_F   1.16  0.10 
       P0_M   1.07  0.35 
       3w_F   1.33  0.10 
       3w_M - 1.09  0.32 
       4w_F - 1.26  0.07 
       4w_M - 2.26  0.01 
       5w_F   1.62  0.01 
       5w_M - 1.03  0.45 
       7w_F - 1.03  0.44 
       7w_M - 1.07  0.37 
       10w_F - 1.20  0.21 
      10w_M - 1.09  0.32 
            
PAK1 O88643 T423  E9_F - 1.23  0.23 
       E9_M   1.14  0.35 
       E14_F   1.26  0.07 
       E14_M   1.01  0.48 
       P0_F - 1.20  0.15 
       P0_M - 1.03  0.46 
       3w_F   1.60  0.04 
       3w_M - 1.04  0.42 
       4w_F   1.20  0.16 
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       4w_M - 1.31  0.05 
       5w_F   1.03  0.46 
       5w_M   1.13  0.31 
       7w_F   1.09  0.36 
       7w_M - 1.17  0.23 
       10w_F - 1.17  0.23 
       10w_M   1.14  0.30 
            
Profilin1 P62962 S138  E9_F - 3.49  0.01 
       E9_M   1.48  0.20 
       E14_F   2.70  0.01 
       E14_M   1.69  0.02 
       P0_F - 1.24  0.25 
       P0_M - 1.73  0.08 
       3w_F   2.61  0.02 
       3w_M - 1.32  0.28 
       4w_F   3.03  0.01 
       4w_M   1.36  0.18 
       5w_F   1.94  0.02 
       5w_M - 2.39  0.01 
       7w_F - 1.16  0.32 
       7w_M - 3.01  0.01 
       10w_F - 1.11  0.30 
       10w_M   1.48  0.03 
            
AKT1 P31750 S473  E9_F   1.64  0.09 
       E9_M - 3.62  0.01 
       E14_F   2.04  0.01 
       E14_M   1.05  0.41 
       P0_F - 1.81  0.01 
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       P0_M   1.03  0.46 
       3w_F - 1.34  0.13 
       3w_M - 1.12  0.31 
       4w_F - 1.69  0.03 
       4w_M - 1.04  0.44 
       5w_F - 1.31  0.26 
       5w_M   1.82  0.02 
       7w_F - 1.04  0.45 
       7w_M - 1.41  0.15 
 
     10w_F   1.25  0.20 























4.2.1.1.1 Rho-associated protein kinase (ROCK2)  
 
             ROCK 2 is critical for maintaining the spine morphology and regulating neuronal actin, 
which ultimately modulates synaptic function. Dendritic spines are specialized structures required 
for normal synaptic physiology and have been shown to be altered in the HD state (Chelly and 
Mandel, 2001; Zhou et al., 2009). Two mammalian ROCK homologs have been identified, 
including ROCK1 (also called Rho-kinase β) and ROCK2 (also known as ROKα) (Nakagawa et 
al., 1996). The expression of ROCK2 is higher in the brain compared to ROCK1. ROCK2 
knockout mice have a normal gross brain anatomy, but show changes in synaptic transmission 
(Zhou et al., 2009). The actin cytoskeleton is altered in these mice thus making ROCK2 essential 
for the normal morphology and functioning of the synapses (Zhou et al., 2009). It is known that 
ROCK2 can directly phosphorylate and activate LIM kinases, which in turn phosphorylate and 
inactivates cofilin thus affecting actin depolymerization (Maekawa et al., 1999) (Figure 4.6). The 
phosphorylation of ROCK2 S1366 is conserved in vertebrates and is required for the activation of 
the enzyme (Chuang et al., 2012). It is phosphorylated upon DNA damage, probably by ATM or 
ATR cellular kinases that are well-characterized in the DNA-damage response (Cara et al., 2016).  
            Representative Western blots for both sexes at different developmental time points are 
shown below with phospho-ROCK2 (160kD) represented in Figure 4.7A and total-ROCK2 in 
Figure 4.7B. Assessments of the relative phosphorylation confirmed that phosphorylation of 
ROCK2 S1366 was significantly decreased in lysates derived from the whole brains of female HD 
mice at E9 and striatum at 10w.  However, the relative phosphorylation of ROCK2 at S1366 in 
E14 females was significantly increased in HD. The other time points did not show any significant 
difference in the relative phosphorylation status of ROCK2 (Figure 4.7C), although the peptide 





Figure 4.7A: Western blot analysis of phospho-ROCK protein levels. 
Representative blots for phospho-ROCK (160kD) across eight time points and both sexes. The 
same membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, 





Figure 4.7B: Western blot analysis of total-ROCK protein levels. 
Representative blots for total-ROCK (160kD) across eight time points and both sexes. The same 
membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, H = 







Figure 4.7C: Quantification of phospho-ROCK2 ratio in brain samples of HD versus healthy 
control (HC) mice. 
Shown here are bar-graphs representing the densitometry data of phospho-ROCK2 expression 
derived from Western blotting experiments using brain tissue lysates from HD and healthy control 
(HC) mice. The densitometric data were quantified as the ratio of the expression of phospho-
ROCK2 (S1366) to total-ROCK2. Protein levels of both phospho-ROCK2 and total-ROCK2 were 
normalized to α-tubulin expression. Bar graph shows mean ± standard deviation, *P < 0.05, **P < 
0.005, n = 3 experiments, unpaired t-test. HC = Healthy control, HD = Huntington disease. E = 






4.2.1.1.2 p21 activated kinase (PAK) 
 
            The PAK family consists of group I PAKs, including PAK1, PAK2 and PAK3 that are 
activated by GTP bound, RAC/CDC42. The second, more recently discovered group II PAKs 
include PAK4, PAK5 (also known as PAK7) and PAK6. The expression of PAK1 and PAK3 is 
very high in the brain while PAK2 expression is ubiquitous (Fuchsova et al., 2016; Kichina et al., 
2010; Kim et al., 2016). PAK1 has been shown to increase the aggregation of mHtt, thereby, 
modulating its toxicity (Luo et al., 2008). The inhibition of PAK1 is also protective in HD (Ma et 
al., 2012). When activated, PAK1 is a known regulator of the actin cytoskeleton and dendritic 
spine morphology (Kichina et al., 2010; Luo et al., 2008). Its role in the loss of dendritic spines 
and cognitive deficits in AD have been well established (Ma et al., 2012). PAK1 regulates the 
actin cytoskeleton through LIMK1, which ultimately regulates cofilin (Kichina et al., 2010; Zhou 
et al., 2009) . It has been suggested that ROCK2 is mainly important for basal cofilin regulation, 
whereas PAK1 is specifically important for activity-dependent cofilin regulation (Asrar et al., 
2009) (Figure 4.6). Apart from cytoskeletal dynamics, PAK1 has other roles in cell motility, the 
cell cycle, cell survival and death (Kichina et al., 2010; Parvathy et al., 2016). PAK1 T423 is a 
conserved site in its activation loop, which is activated by kinases (3-phospho-inositide dependent 
kinase-1 (PDK1)) and deactivated by phosphatases (Serine-threonine phosphatase PP2A). 
Autophosphorylation of T423 (T402 for PAK 2 and T421 for PAK 3) is required for the activation 
of PAK.  
            An equal amount of protein was analyzed by Western blotting using phosphospecific 
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antibodies and normalized to total protein levels. Representative Western blots for both sexes are 
shown below with phospho-PAK1 represented in Figure 4.8A and total PAK in Figure 4.8B. 
Assessments of the relative phosphorylation confirmed that phosphorylation of PAK1-T423 was 
significantly decreased in the lysates derived from the whole brains of HD mice at E9 and E14 in 
both sexes. The 3w time point shows the opposite results for both sexes. Females show an increase 
and males show a decrease in the protein levels of PAK, revealing a sex difference. There was an 
increase in the relative expression of PAK in 4w males and 10w males however, the comparative 
analysis of males and females at birth, 5w and 7w did not show any significant differences 
compared to the peptide array results (Table 4.4). That data was also confirmed by the WB results, 








Figure 4.8A: Western blot analysis of phospho-PAK protein levels. 
Representative blots for phospho-PAK (65kD) across eight time points and both sexes. The same 
membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, H = 





Figure 4.8B: Western blot analysis of total-PAK1/2/3 protein levels. 
Representative blots for total-PAK1/3 (68kD) and total-PAK2 (61kD) across eight time points and 
both sexes normalized to α-tubulin (50kD). C = Control mouse, H = HD mouse, E = embryonic, 







Figure 4.8C: Quantification of phospho-PAK ratio in brain samples of HD versus healthy 
control (HC) mice. 
Shown here are bar-graphs representing densitometry data of phospho-PAK expression derived 
from Western blotting experiments using brain tissue lysates of HD and healthy control (HC) mice. 
The densitometric data were quantified as the ratio of the expression of phospho-PAK (T423) to 
total PAK. Protein levels of both phospho-PAK and total PAK were normalized to α-tubulin 
expression. Bar graph shows mean ± standard deviation, *P < 0.05, **P < 0.005, ***P < 0.001, n 
= 3 experiments, unpaired t-test. HC = Healthy control, HD = Huntington disease, E = embryonic, 







            The LIM kinase family of serine/threonine kinases includes LIMK1 and LIMK2 that play 
a key role in actin and microtubule dynamics (Cuberos et al., 2015; Dong et al., 2012; Meng et 
al., 2002). Both kinases are related, with the former being highly expressed in the brain and the 
latter being ubiquitously expressed. The LIM kinases are activated by Rho kinase (ROCK) and 
PAK1 and 4, which leads to the modulation of cofilin (Ohashi et al., 2000). These upstream kinases 
phosphorylate LIMK1 T508 within the activation loop which is the site of its activation 
(Narayanan et al., 2016; Ohashi et al., 2000). The role of LIMK in microtubule dynamics in neural 
networks has not been studied well due to the complexities of the nervous system (Cuberos et al., 
2015). The transient overexpression of LIMK1 accelerates axon formation in mice and a prolonged 
overexpression of LIMK1 leads to axon retraction (Dong et al., 2012).  
            Representative Western blots for both sexes are shown below with phospho-LIMK1 
represented in Figure 4.9A and total LIMK1 in Figure 4.9B. The antibodies did not detect any 
expression at E9 for both phospho and total protein. Assessments of the relative phosphorylation 
confirmed that LIMK1 T508 was significantly decreased in lysates derived from the striatum of 
female HD mice at 3w. The relative phosphorylation in 4w female and male HD mice exhibited a 
significant decrease. Males at 7w showed a significant reduction in the expression of LIMK1 
compared to females with HD, indicating a sex difference. At 10w, both sexes showed a significant 
reduction in the relative phosphorylation of LIMK1. No significant changes were observed in the 





Figure 4.9A: Western blot analysis of phospho-LIMK protein levels. 
Representative blots for phospho-LIMK1 (73kD) across seven time points and both sexes. The 
same membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, 





Figure 4.9B: Western blot analysis of total-LIMK protein levels. 
Representative blots for total-LIMK1 (73kD) across seven time points and both sexes. The same 
membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, H = 






Figure 4.9C: Quantification of phospho-LIMK1 ratio in brain samples of HD versus healthy 
control mice. 
Shown here are bar-graphs representing the densitometry data of phospho-LIMK1 expression 
derived from Western blotting experiments using brain tissue lysates of HD and healthy control 
(HC) mice. The densitometric data were quantified as the ratio of the expression of phospho-
LIMK1 to total-LIMK1. Protein levels of both phospho-LIMK1 and total-LIMK1 were normalized 
to α-tubulin expression. Bar graph shows mean ± standard deviation, *P < 0.05, **P < 0.005, ***P 
< 0.001, n = 3 experiments, unpaired t-test. HC = Healthy control, HD = Huntington disease, E = 







            Cofilin plays an important role in actin dynamics by modulating actin polymerization and 
depolymerization. Apart from the severing activity it also induces dendritic nucleation and 
debranching. Cofilin is found in various compartments of the cells, including the cytoplasm and 
nucleoplasm, and forms stable heteropolymers with F‑actin in the nucleus (Wioland et al., 2017). 
Cofilin that is not phosphorylated at S3 is involved in the reversible interactions with F and G-
actin. These interactions are involved in the regulation of cofilin after activation or its positioning 
in the cellular compartment (Bamburg and Bernstein, 2016; Munsie and Truant, 2012). The 
phosphorylation of cofilin at S3 leads to its deactivation leading to depolymerizing actin filaments. 
Conversely, the dephosphorylation of cofilin allows its binding to actin thereby promoting its 
polymerization. Slingshot (SSH) is the major phosphatase responsible for dephosphorylating 
cofilin at S3. The regulation of LIMK and SSH affects the phosphorylation of cofilin at S3 and 
ultimately its interaction with actin. Protein kinase D (PKD) inactivates SSH1L, a member of the 
SSH family, and activates LIMK1; therefore, inhibiting cofilin dephosphorylation. Notably 
calcineurin triggers cofilin dephosphorylation through the activation of SSH1L, whereas 
Ca2+/calmodulin dependent protein kinase II (CaMKII) negatively regulates SSH1L (Wang et al., 
2005). This indicated that calcineurin and CaMKII act as molecular switches controlling Ca2+-
dependent cofilin activation (Figure 4.6).  
            Representative Western blots for both sexes are shown below with phospho-cofilin 
represented in Figure 4.10A and total cofilin in Figure 4.10B. Assessments of the relative 
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phosphorylation confirmed that cofilin S3 was significantly increased in the lysates derived from 
the whole brains of females, and decreased in male HD mice at E9 thus, indicating a sex difference. 
The phosphorylation of cofilin in females indicates that the depolymerization of actin and the 
reduced phosphorylation in males leads to actin polymerization. At E14, there was an increase in 
the relative phosphorylation in whole brain samples from females with HD. At 3w both the male 
and female striatal samples exhibited increases in the relative phosphorylation of cofilin. At 4w 
the cofilin levels decreased in the female HD striatum. Both the male and female relative 
expression levels of cofilin were reduced at 5w. At 7w only females and at 10w only males showed 
a reduction in the relative phosphorylation of cofilin, suggesting a sex difference in disease 










Figure 4.10A: Western blot analysis of phospho-cofilin protein levels. 
Representative blots for phospho-cofilin (19kD) across eight time points and both sexes. The same 
membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, H = 





Figure 4.10B: Western blot analysis of total-cofilin protein levels. 
Representative blots for total-cofilin (19kD) across eight time points and both sexes. The same 
membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, H = 







Figure 4.10C: Quantification of phospho-cofilin ratio in brain samples of HD versus healthy 
control mice. 
Shown here are bar-graphs representing densitometry data of phospho-cofilin expression derived 
from Western blotting experiments using brain tissue lysates of HD and healthy control (HC) mice. 
The densitometric data were quantified as the ratio of the expression of phospho-cofilin to total 
cofilin. Protein levels of both phospho-cofilin and total cofilin were normalized to α-tubulin 
expression. Bar graph shows mean ± standard deviation, *P < 0.05, **P < 0.005, n = 3 experiments, 








            The Slingshot (SSH) family of protein phosphatases include three members, namely SSH1, 
SSH2 and SSH3. The regulation of cofilin is controlled by LIMKs and SSH phosphatases through 
phosphorylation (inactivation) and dephosphorylation (activation) at S3, respectively. The 
regulation between phospho-cofilin and cofilin level determines actin polymerization in growth 
cone motility, neurite outgrowth and axon guidance (Ohta et al., 2003). One study showed that 
SSH1 is activated by ROS, which subsequently activated the cofilin proteins that form cofilin rods 
and cause neurite atrophy (Kim et al., 2009) (Figure 4.6). Calcium mediates the activation of SSH 
via the activation of calcineurin (Wang et al., 2005). Phosphorylation of SSH1 at S978 increases 
its phosphatase activity.  
        Representative Western blots for both sexes are shown below with phospho-SSH1L 
represented in Figure 4.11A and total SSH1L in Figure 4.11B. The expression of phospho and 
total-SSH1L were not detected at E9. Assessment of the relative phosphorylation confirmed that 
SSH1L at S978 was significantly decreased in the lysates derived from the whole brain of female 
HD mice at E14 and correspond to the increase in cofilin phosphorylation. The relative 
phosphorylation at birth in males was significantly decreased in HD striatum samples.  At 3w, both 
sexes had increased expression of SSH1L compared to control samples. At 5w there is a significant 
increase in the expression of SSH1L in male. The analysis showed that the rest of the striatal 
samples did not exhibit a significant difference in the relative phosphorylation status of SSH1L 






Figure 4.11A: Western blot analysis of phospho-SSH1L protein levels. 
Representative blots for phospho-SSH1L (150kD) across eight time points and both sexes. The 
same membranes were also blotted for α-tubulin as a loading control (50kD). No expression was 
observed at E9. C = Control mouse, H = HD mouse, E = embryonic, P0 = at birth, w = week. 





Figure 4.11B: Western blot analysis of total-SSH1L protein levels. 
Representative blots for total-SSH1L (150kD) across eight time points and both sexes. The same 
membranes were also blotted for α-tubulin as a loading control (50kD). No expression was 







Figure 4.11C: Quantification of phospho-SSH1L ratio in brain samples of HD versus healthy 
control mice. 
Shown here are bar-graphs representing densitometry data of phospho-SSH1L expression derived 
from Western blotting experiments using brain tissue lysates of HD and healthy control (HC) mice. 
The densitometric data were quantified as the ratio of the expression of phospho-SSH1L to total 
SSH1L. Protein levels of both phospho-SSH1L and total SSH1L were normalized to α-tubulin 
expression. Bar graph shows mean ratio ± SD, *P < 0.05, **P < 0.005, ***P < 0.001, n = 3 
experiments, unpaired t-test. HC = Healthy control, HD = Huntington disease, E = embryonic, P0 





4.2.1.1.6 Profilin-1  
 
            Profilin is an actin binding protein with four isoforms with tissue-specific expressions 
(Burnett et al., 2008). Profilin 1 is expressed in all tissues, profilin 2 is specifically expressed in 
the brain, and profilins 3 / 4 are expressed in the testis.  Profilin 1 binds to Htt protein causing a 
progressive loss of mHtt seen in the cortex of HD patients by reducing its aggregation (Burnett et 
al., 2008; Posey et al., 2018). The loss of profilin further leads to the imbalance in the F/G actin 
ratio, which ultimately affects actin polymerization (Burnett et al., 2008). ROCK1 phosphorylates 
profilin 1 at S138 and reduces its affinity for G-actin (Narayanan et al., 2016). This prevents the 
interaction of profilin 1 with Htt; thus, preventing the inhibition of mHtt aggregation (Burnett et 
al., 2008; Shao et al., 2008).  
            Representative Western blots for both sexes are shown below with phospho-profilin 1 
represented in Figure 4.12A and total profilin in Figure 4.12B. Assessments of relative 
phosphorylation confirmed that profilin S138 was significantly decreased in the lysates derived 
from the whole brains of female HD mice at E9, which was similar to the peptide array output 
(Table 4.4).  Phosphorylation increases were observed in the HD brains of both sexes at E14, again 
agreeing with the direction observed in the peptide array outputs. At 3w, the shift was observed in 
both sexes showed a significant increase in HD samples. At 7w, a difference was observed between 
male and females where only the male HD mice showed a significant difference between HD and 
HC. At 10w, both the female and male HD lysates exhibited a reduction in the expression of 
profilin 1. There were no significant changes in expression observed in the 4 and 5w samples, as 





Figure 4.12A: Western blot analysis of phospho-profilin protein levels. 
Representative blots for phospho-profilin (15kD) across eight time points and both sexes. The 
same membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, 





Figure 4.12B: Western blot analysis of total-profilin protein levels. 
Representative blots for total-profilin (15kD) across eight time points and both sexes. The same 
membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, H = 







Figure 4.12C: Quantification of phospho-profilin 1 ratio in brain samples of HD versus 
healthy control mice. 
Shown are bar-graphs representing densitometry data of phospho-profilin 1 expression derived 
from Western blotting experiments using brain tissue lysates of HD and healthy control (HC) mice. 
The densitometric data were quantified as the ratio of the expression of phospho-profilin 1 to total-
profilin. Protein levels of both phospho-profilin 1 and total-profilin were normalized to α-tubulin 
expression. Quantitative data were compared between groups using t-tests (males-M and females-
F). Bar graph shows mean ± standard deviation, *P < 0.05, **P < 0.005, ***P < 0.001, n = 3 
experiments, unpaired t-test. HC = Healthy control, HD = Huntington disease, E = embryonic, P0 







            AKT is a Serine/Threonine kinase whose activation occurs downstream of PI3K, and has 
many multifunctional key nodes downstream. AKT has three isoforms named AKT 1, 2 and 3 and 
is considered a master regulator for a number of biological processes such as proliferation, cell 
survival, growth, and neurogenesis (Colin et al., 2005; Lievens et al., 2008; Maddika et al., 2008; 
Sugiyama et al., 2019). PI3K activation leads to the phosphorylation of two key residues on AKT1, 
including T308 in the activation loop, and S473 in a C-terminal hydrophobic motif (Manning and 
Toker, 2017). The phosphorylation of both residues are required to attain maximum functionality 
by the kinase. PP2A and PTEN are major phosphatases that directly inactivate AKT (Phadngam 
et al., 2016). The appearance of this particular isoform in the significantly differentiated peptide 
array dataset was recognized as important and appropriate for validation.  
            Representative Western blots for both sexes are shown below with phospho-AKT1 
represented in Figure 4.13A and total AKT1 in Figure 4.13B. Assessments of the relative 
phosphorylation confirmed that phospho-AKT1 S473 was significantly increased in the lysates 
derived from the whole brain of both sexes HD mice at E9. The relative phosphorylation at birth 
was also significantly increased in females and males. At 3w, there was an increase in the relative 
phosphorylation of AKT1 in females and at 5w there was a decrease in the relative phosphorylation 
in males. Those findings were opposite to the results obtained by the peptide array (Table 4.4). At 
10w phosphorylation was increased in males. The results from the later time points suggest a sex 
difference. E14, 4w and 7w did not show any significant changes in AKT1 phosphorylation, as 





Figure 4.13A:  Western blot analysis of phospho-AKT1 protein levels. 
Representative blots for phospho-AKT1 (60kD) across eight time points and both sexes. The same 
membranes were also blotted for α-tubulin as a loading control (50kD). C = Control mouse, H = 






Figure 4.13B: Western blot analysis of total-AKT1 protein levels. 
Representative blots for total-AKT1 (60kD) across eight time points and both sexes normalized to 







Figure 4.13C: Quantification of phospho-AKT1 ratio in brain samples of HD versus healthy 
control mice. 
Shown here are bar-graphs representing densitometry data of phospho-AKT1 expression derived 
from Western blotting experiments using brain tissue lysates from HD and healthy control (HC) 
mice. The densitometric data were quantified as the ratio of the expression of phospho-AKT1 to 
total AKT1. Protein levels of both phospho-AKT1 and total AKT1 were normalized to α-tubulin 
expression. Quantitative data were compared between groups using t-tests (males-M and females-
F). Bar graph shows mean ± standard deviation, *P < 0.05, **P < 0.005, ***P < 0.001, n = 3 
experiments, unpaired t-test. HC = Healthy control, HD = Huntington disease, E = embryonic, P0 





            Analysis of the effects of the peptides involved in cytoskeletal signaling suggests that the 
phosphorylation of the upstream kinases, ROCK2 and PAK1, were dysregulated at the embryonic 
stage of development. The phosphorylation of the kinase and phosphatase upstream of actin 
(LIMK1, SSH1L) along with cofilin and profilin were found to be dysregulated around the same 
time as mHtt appeared in the brain, or at later stages of disease. These are tabulated for a 
comprehensive summary and the ease of visualization in Table 4.4. Therefor it can be suggested 
that there is evidence of both neurodevelopmental changes, as well as sex specific differences in 
the progression of the disease which is observed as the dysregulated kinase signaling. 
 
 
Table 4.14: Summary of the significantly hyper- (pink) and hypo- (green) phosphorylated 
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            Western blot analyses was used in an attempt to independently validate the peptide array 
data following which I decided to identify the upstream kinases responsible for phosphorylating 
these targets, by using online tools. NetworKIN platform was used to predict candidate kinases 
upstream of the phosphosites determined from peptide array analyses utilizing neural tissue from 
HD mice. Significantly hyper-phosphorylated or hypo-phosphorylated phosphosites from the 
peptide array were used to predict upstream kinases for all the time points and both sexes using 
NetworKIN. The resulting predicted annotations were filtered using a NetworKIN confidence 
score cut-off of 3.0 and a NetworKIN score-difference cut-off of 4.0. (Linding et al., 2008). The 
score-difference defines the maximum difference between the best prediction and the second-best 
prediction. The identified kinases for hyper- and hypo-phosphorylated phosphosites were plotted 
on a mammalian kinase-dendrogram generated using KinMapbeta. A cut-off score of 30 was used 
for the NetworKIN output which generated a list of predicted kinases that were represented on the 




            As mentioned earlier, a NetworKIN cut off score was used to short list the kinases to be 
represented on a dendrogram (or kinome tree) generated by KinMap. The kinome tree allows the 
visualization of the different kinases from a complex dataset (Eid et al., 2017) to gain a better 
understanding of the biology from high throughput data. The kinases were represented on the 
kinome tree in the form of a circle or square. A circle was used to represent the female dataset and 
squares for males. The candidate kinases predicted to target the upregulated phosphosites are 
represented in red and downregulated phosphosites are represented in green. The color blue was 
used for upregulated phosphosites observed in only one sex with and yellow for downregulated 
phosphosites observed in only one sex. The size of the circles or squares is determined by the 
NetworKIN score, with a higher score having a larger representation on the dendrogram i.e. 
regulating more peptides on the array. Manning et al. used the underlying sequences to divide 
nearly 540 kinases into eight typical and 13 atypical groups (Manning et al., 2002) as listed earlier.  
            After shortlisting the kinases with the NetworKIN a cut-off score of 30 these kinases were 
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then uploaded on the KinMap online tool used to generate dendrograms, visually representing the 
kinases. Based on the peptide array results KinMap represented the predicted kinases that were 
predicted to be dysregulated in HD mice (Supplementary Figures 1.1-1.8). Panel A shows the 
kinases dysregulated in females and the panel B represents males. The dendrograms show subtle 
differences in the predicted kinases, and indicate towards sex and developmental differences 
within the disease process. The difference in the upstream predicted kinases is represented in the 
dendrograms in the appendix and supplementary table S8 highlights them. These results emphasize 
the importance of cytoskeletal system dynamics and upstream kinases regulating the disease 
process. PAKs and GSKs are involved in cytoskeletal dynamics and are upstream of actin and 
microtubules, respectively. The roles of Ephrins on the other hand have been well studied in neural 
development, cytoskeletal dynamics, axon guidance and synaptogenesis (Boyd et al., 2014; Huot, 
2004; Xu and Henkemeyer, 2012). Another prominent family of kinases predicted were the 
CaMKs, of which one example is Ca2+/calmodulin-dependent protein kinase II (CaMKII), which 
negatively regulates SSH1L activity, and thus, plays an important role in actin cytoskeletal 
reorganization (Zhao et al., 2012). Ca2+-induced cofilin dephosphorylation is mediated by 
calcineurin-dependent activation of SSH1L, cofilin and LIMK1 (Zhao et al., 2012). ATM, which 
is an upstream predicted kinase in NSCs was also one of the upstream kinases identified in the 
murine dataset. A study has showed that small-molecule inhibitors targeting ATM ameliorates 
mHtt toxicity in cells and animal models (Cara et al., 2016; Lu et al., 2014). Overall, the findings 
indicate a dysregulated cytoskeleton, developmental variance and sex differences in the disease 
progression, which needs further investigation.  
 
4.2.4 Discussion      
 
 
            Decades ago, neurodegeneration was not well understood since the life expectancy of 
individuals was not as long as it is currently. The 2000’s showed an increase in better 
understanding of the disease process and finding some treatments for neurodegenerative disorders. 
The auto phosphorylation of ROCK2 at S1366 does not affect its kinase activity, but could be a 
contributor to protein subcellular localization. ROCK 2 has multiple downstream targets that affect 
the regulation of cell shape, motility, survival and apoptosis (Koch et al., 2018; Koch et al., 2014; 
Yan et al., 2019). One of the most important effects of activated ROCK is the regulation of the 
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actin cytoskeleton through the phosphorylation of LIMK1 and LIMK2. LIMK phosphorylates 
cofilin, which depolymerizes or severs the actin filament. This arrests neurite outgrowth and leads 
to an abundance of stable actin filaments. Notably, knockdown of ROCK2 prevents apoptosis and 
increases AKT activity (Koch et al., 2014). Several studies have also shown an increase in ROCK2 
and its downstream targets, including LIMK1 and cofilin in patients with neurodegenerative 
disorders such as ALS and AD (Chuang et al., 2012; Koch et al., 2018; Koch et al., 2014; 
Narayanan et al., 2016). Another regulator of the actin cytoskeleton and dendritic spine 
morphogenesis is the RAC/CDC42-activated kinase, PAK1. PAK1 interacts with Htt and enhances 
the aggregation of mHtt, thus inducing toxicity, while inhibition of PAK1 protects against HD 
symptoms (Ma et al., 2012). Studies have shown that PAK1 co-localizes with mHtt aggregates in 
cell lines and in human HD brains, thus, suggesting that it plays a key role in the expansion of the 
polyQ tract that leads to the aggregation of mHtt (Luo et al., 2008; Ma et al., 2012). Notably, there 
is a progressive loss of profilin in presymptomatic HD gene carriers (Burnett et al., 2008). A study 
reported that the overexpression of profilin abolished mHtt toxicity in cells; thus, extending the 
life span of Drosophila (Posey et al., 2018). Profilin can promote actin polymerization or sequester 
G-actin, therefore, causing different effects under different conditions. The relative levels of F 
(polymerized) and G actin (monomeric) are affected in HD following the induction of mHtt, but 
no changes are observed with WT Htt (Posey et al., 2018).  It is interesting to note that profilin 
was a significantly phosphorylated peptide in the kinome analysis. Its interactions with cofilin 
makes it a major player in the dysregulation of cytoskeletal regulation in R6/2 HD mice. As 
depicted by the results LIMK1 cofilin and SSH1L play a major role in actin dynamics in HD. 
Phosphorylation of cofilin causes its deactivation and the process is reversed by the phosphatase 
SSH1L. Both PAK and ROCK2 regulate LIMK1, which ultimately affects the actin cytoskeleton, 
axonal transport, and synaptic disruption. SSH1L is involved in Ca+2-mediated cofilin 
dephosphorylation mediated by calcineurin, which is the major phosphatase in this study which 
could have a major role in the disease process.   
            Age related neurodegenerative disorders showed an increase in the DNA damage and 
dysregulation of energetic mechanism which leads to cell death. Recently both ATM (DNA 
damage) and PDHK1 (energy metabolism) have been shown to be dysregulated in HD (Lu et al., 
2014; Vallee et al., 2018) and they appeared as the predicted upstream kinases in this dataset. It 
has been shown that mHtt causes an aberrant increase in the ATM signaling in HD and ATM 
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inhibitors appear to be neuroprotective though the mechanisms of the increase are yet to be 
understood (Lu et al., 2014). The brain uses 70% of the energy produced hence ATP is the primary 
determinant of neuronal viability. The inactivation of PDHK1 in HD is due to an increase in the 
WNT/β-catenin signaling (Vallee et al., 2018). The kinome profiling predicted by in silico analysis 
that these two kinases are important in the disease process. Hence the regulation of aerobic 
glycolysis and reduction of ATM signaling should be further studied as they might be useful 
therapeutic targets for HD. 
            Finally, the peptide array analyses revealed that a number of phosphorylated peptides could 
not be validated. This is a drawback of peptide array analysis and needs to be addressed. 
Furthermore, it has been noted that 50-70% of the information from the peptide arrays is lost due 
to technical reasons during data normalization (Scholma et al., 2016). Therefore, the use of quasi-
stringent t-testing (P < 0.1/0.2) in the analyses allowed  to reduce the bias due to stringent statistical 
thresholds (Kindrachuk et al., 2012; Napper et al., 2015; Scholma et al., 2016). These adjustments 
are required to get a much larger dataset supported by bioinformatics analysis to generate 
significant biologically relevant result. In conclusion these peptide arrays offer an effective high 
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5. GENERAL DISCUSSION  
 
5.1 Cytoskeletal dynamics dysregulated in HD NSCs and R6/2 mice 
 
            Kinome profiling has been successfully used to study neurodegenerative disorders 
(Hoozemans et al., 2012; Meng et al., 2016; Rosenberger et al., 2016) and cytoskeletal dynamics 
have been previously characterized to be dysregulated in neurodegenerative diseases such as 
Alzheimer’s disease (Eira et al., 2016; Majumder et al., 2017). The objective of this study was to 
determine the involvement of protein kinases in HD pathogenesis and this study uses kinome 
profiling to identify the pathways dysregulated in NSCs and R6/2 HD mice. The analysis of both 
the stem cells and murine tissues determined that the cytoskeletal dynamics as one of the major 
pathways dysregulated. This was followed by in silico analyses of the phosphosites which 
uncovered upstream kinases such as ATM and GSK3β which have been previously identified as a 
therapeutic target for HD (Fernandez-Nogales et al., 2015; Lu et al., 2014). ATM is a DNA 
damage sensor, and it has been shown that the DNA damage in HD is caused by dysfunction of 
the mutant huntingtin protein in DNA repair followed by an increase in ROS leading to oxidative 
stress (Maiuri et al., 2017). GSK3β on the other hand is reduced in HD brain and plays an important 
role in reducing ubiquitination-proteosomal degradation and suppressing polyQ protein 
aggregation (Lee et al., 2016). These results could help in identifying therapeutic targtes to treat 
HD by regulating these kinases. This study allowed us to uncover the different phosphoryation 
status of the key players in the cytoskeltal dynamics - ROCK2, PAK1, Profilin, AKT1, LIMK1, 
Cofilin and SSH1L. In general most of the peptides had the same directionality (hyper- or hypo-
phosphorylated) in Westerns as in peptide arrays in most of the developmental stages but. In a few 
developmental time points it was reversed and the complexity of the signaling is represented in 









Table 5.1 Comparative summary of the significantly hyper- (pink) and hypo- (green) 
phosphorylated proteins based on peptide array and Western blot results of R6/2 mouse 
model. The darker shades of pink and green are the results which show opposite trends in kinome 
vs Western and are statistically significant. NE = no expression at specified time point. * indicates 








E9 E14 P0 3w 4w 5w 7w 10w
F M F M F M F M F M F M F M F M
ROCK2 Kinome * * * * * * * *
Western * * *
PAK Kinome * * * * * * * *
Western * * * * * * * *
Profilin Kinome * * * * * * * * * * * * * *
Western * * * * * * * *
AKT1 Kinome * * * * * * * * * *
Western * * * * * * *
LIMK1 Western NE NE * * * * * *
Cofilin Western * * * * * * * * * *
SSH1L Western NE NE * * * * *
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            Signaling does not always occur in a linear fashion but via cascades with one protein 
catalyzing the phosphorylation of a second protein. The number of proteins receiving a signal can 
multiply very rapidly in each step of the cascade thus amplifying the signal. Some of these cascades 
have proteins which are involved in multiple pathways and may lead to the compensatory output 
in one pathway and exaggerated in the other. The native phosphorylation events occurring at the 
cellular levels require a relevant biological stimuli or the absence of it for a more appropriate 
representation of physiological kinase activities. In the past a number of low throughput techniques 
have been used to study a disease process. They analyzed one or few molecules at a time. While 
such techniques are useful and informative they are time consuming and cannot recapitulate these 
complex signaling changes. They are not conducive to understanding the intricate biological 
interactions and cannot generate global patterns of signaling. The disadvantage of high throughput 
studies is that some of these datasets generate complex patterns which might need an increase in 
sample size to reduce inconsistent findings or further analysis of the dataset using computational 
algorithms to derive meaningful data.            
            The phosphorylation profiles of the protein samples were compared as percentage value. 
The hyper- and hypo phosphorylated peptides list was generated using the P-value cut off and a 
percentage was obtained using the total number of peptide printed on the array. The results were 
depicted separately for both male and females and a combined value as shown in Table 5.2. An 
important difference observed was between the two sexes at 4w and 7w which developmentally 
correlated with the appearance of mHtt in the striatum and decreased body weight respectively. 
The hyperphosphorylated peptides in females at 4w is ~40% and hypophosphorylated ~27% and 
the values are reversed in males in the same time point. Similarly at 7w hyperphosphorylated 
peptides in females were ~45% and hypophosphorylated~22% and the values reversed on males. 
This is indicative of potential sex differences in the development of the disease considering the 
time points being developmentally significant though further investigation is required for a 








Table 5.2: The percentage of peptides significantly (de) phosphorylated in the mouse and 
NSCs. A P-value cut off was used to generate a list of hypo-and hypo phosphorylated peptides and 
a percentage value derived using the total number of peptide printed on the array. The percentage 
value higher in the hyper- or hypophosphorylated results is highlighted in bold.  
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            Huntington Disease mouse models and other studies provided evidence that sex may 
account for the variability in the disease. The scientific evidence that estrogen is neuroprotective 
in HD is limited and there are conflicting information available. Some studies suggest female sex 
is detrimental while others have shown it being neuroprotective (Foroud et al., 1999; Zielonka et 
al., 2013). The levels of neurotrophic factors (GDNF, BDNF) increases in the striatum upon an 
increase in the estrogen levels (Campos et al., 2012). Estrogen also decreases the production of 
ROS by increasing the expression of scavengers like superoxide dismutase, glutathione peroxidase 
etc. (Wang et al., 2001). Estrogen also protects the mitochondrial membrane potential thereby 
preventing ATP depletion and suppresses the free radical production (Simpkins et al., 2010). These 
studies can open avenues for targeted therapy but specific mechanisms of neuroprotection need to 
be well understood. While the results of this global analysis using peptide array definitely indicate 
towards differences in the sexes.  
            MAPK/ERK and PI3K/AKT pathways are downstream targets of 17β-estradiol an estrogen 
steroid hormone which exerts neuroprotective effect from ROS, glutamate and misfolded protein 
toxicity in the neurons (Figure 5.1) (Smith and Dahodwala, 2014). The signal cascades are broadly 
involved in cell survival and are affected due to a decrease in the ratio of Bcl-2 (pro-survival): 
BAD (pro-apoptotic) proteins in neurodegenerative disorders. Activation of MAPK/ERK leads to 
the inhibition of pro-apoptotic proteins such as BAD and GSK3β (Bourque et al., 2009). Both ERα 
and ERβ receptors localize in the mouse striatum which is the most affected tissue in HD (Kuppers 
and Beyer, 1999). GSK3β phosphorylates tau which leads to microtubule dysfunction (Figure 
4.3B) followed by disruption in protein trafficking which ultimately leads to the formation of 
neurofibrillary tangles and finally cell death (Goodenough et al., 2005). Microtubule dynamics can 
be affected if GSK3β is inhibited by estrogen via PI3K/AKT which may affected the cytoskeletal 
signaling as shown in Figure 5.1. The coordination of the actin-microtubule dynamics is required 
to maintain the neuronal structure and function. These cytoskeletal filaments provide cells with 
mechanical stability and organization which is lost in neurodegenerative disorders. A larger cohort 
of animals with equal distribution of both sexes is required to draw definitive conclusions along 
with further elucidation of mechanisms underlying estrogens role in HD. In summary, sex steroid 
hormones and the sex chromosomes might play a vital role in the development of the HD through 
their effects in the basal ganglia networks. A better understanding of the differences in these 





Figure 5.1: Schematic representation of neuroprotective mechanisms of ER signaling. 
Binding of estrogen receptors (ER) by estradiol activates signal cascades that ultimately decrease 
apoptosis of neurons. GSK3β inhibited by estrogen via the PI3K/AKT pathway results in the 
inhibition of apoptosis (Permission to use from Smith and Dahodwala, 2014).  
 
5.2 Limitations of kinome analysis 
 
            Protein phosphorylation is estimated to influence about 30% of the proteome, regulating 
fundamental cellular processes such as cell proliferation, migration, survival, apoptosis etc. All 
these processes are mediated by 525 protein kinases. Kinome analysis allows the measurement of 
intracellular signaling events underlying a disease process. Each kinase has a characteristic 
recognition pattern which catalyzes a specific residue only if the surrounding sequences match the 
pattern. This is a caveat with the kinome analysis since a phosphorylatable amino acid may either 
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be exposed or buried in an intact protein in a conformational context. Kinase have a substrate 
specificity in vivo in a temporal and spatial context. Protein interaction domains exist within the 
kinase which allow the kinase to recognize specific proteins to bind and phosphorylate. This may 
further be triggered upon signaling cues such as stimulation with specific ligands that activate 
upstream receptors. Peptide arrays do not accurately recapitulate these cellular aspects.  
            In the present study commercially available antibodies against specific kinases / 
phosphatases and downstream targets were used to independently validate the peptide array results. 
Other experimental approaches may be used towards further validating and characterizing this 
dataset such as in vitro kinase and phosphatase assays where the appropriate kinase/phosphatase 
may be immunoprecipitated from the HD mouse brain or NSCs and assessed for activation. 
Another challenge with kinome analysis is that it examines just one side of the biological process. 
Protein kinases and phosphatases often act in tandem to perform the phosphorylation and de-
phosphorylation process. The peptide arrays just provide information pertaining to only kinases 
which may be incomplete without the analysis of the phosphatase activity. Adding to this is the 
fact that the buffer used for kinome analysis may not be able to provide the maximal activity of 
each and every kinase. The fact that the peptides printed on the array are manually selected renders 
a level of bias along with the aforementioned constraints therefore adding to the potential 
limitations of kinome analysis.  
            
5.3 Proteome vs kinome: dysregulation in cytoskeletal dynamics  
 
            It is interesting to compare my kinome data with the proteomic analysis from post-mortem 
patient samples. Systematic quantitative proteomics assessing global changes in HD implicated 
Rho proteins, actin cytoskeleton signaling and mitochondrial dysfunction signaling as the most 
altered in HD (Ratovitski et al., 2016). This study utilized the HD human brain tissues to perform 
quantitative proteomics which directly addresses the changes in protein abundances that occur in 
the disease state (Ratovitski et al., 2016). The mass-spectrometrically (MS) identified proteins 
were verified using Western blotting which showed protein expression changes in actin 
cytoskeleton. Their proteomic analysis indicated that changes in the HD brain are consistent with 
the dysfunction of actin cytoskeleton remodeling as shown in the Figure 5.2. It is interesting to 
note that they did not study the rodent samples but despite the difference in the species there was 
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a consistent pathway dysregulated in post-mortem human samples and in my study using R6/2 HD 
mice. Another study focusing on the changes in the striatal proteome of YAC128Q mice used 
liquid chromatography coupled in-line with tandem mass spectrometry (LC-MS/MS) 
(Wegrzynowicz et al., 2012). They identified proteins related to energy metabolism or cellular 
transport/cytoskeleton as most prominent among others. The striatal lysates were used to analyze 
by immunoblotting with antibodies the protein identified in the analyses (Wegrzynowicz et al., 
2012). This along with the previous work clearly implicates dysregulated cytoskeletal dynamics 




Figure 5.2: Quantitative proteomic analysis shows actin cytoskeleton pathway is enriched in 
HD relative to control. 
Ingenuity pathway analysis (IPA) generated figure based on the MS output from brain tissue 







Table 5.1: Main cytoskeletal defects observed in neurodegenerative disorders. 
Cytoskeleton dysfunction Molecular dysregulation Neurodegenerative disorder 
Altered microtubule 
dynamics and axonal 
transport defects 
Decreased α-tubulin acetylation 
AD (Zhang et al., 2014) 
HD (Dompierre et al., 2007) 
CMT (d'Ydewalle et al., 
2011) 
Tau hyper-phosphorylation 
AD (Alonso et al., 
1996, Alonso et al., 1997) 
Increased βIII tubulin levels PD (Cartelli et al., 2013) 
GSK3β hyperactivation AD (Flaherty et al., 2000) 
Mutations in SOD1 ALS (Strom et al., 2008) 
MT severing 
Increased tubulin 
polyglutamylation/recruitment of MT 
severing enzymes 
AD (Zempel et al., 2013) 
Axonal transport defects 
(microtubule 
independent) 
Mutations in molecular motors 
ALS (Munch et al., 2004) 
CMT (Zhao et al., 2001) 
Increased kinesin phosphorylation by 
GSK3β 
AD (Morfini et al., 
2002, Pigino et al., 2003) 
Mutated Huntingtin HD (Trushina et al., 2004) 
Protein aggregation 
AD (Coleman, 
2011, Goldstein, 2012) 
PD (Coleman, 
2011, Goldstein, 2012) 
HD (Coleman, 





AD (Minamide et al., 2000) 
HD (Munsie and Truant, 
2012) 
Hirano bodies AD (Schmidt et al., 1989) 
Cofilin inactivation PD (Bellani et al., 2014) 
Profilin1 mutations ALS (Wu et al., 2012) 
Dysregulation of Rho GTPases 
PD (Zhou et al., 2011) 
CMT (Delague et al., 
2007, Stendel et al., 2007) 
HD (Tourette et al., 2014) 
AD (Mendoza-Naranjo et al., 
2007, Petratos et al., 2008) 





            In summary, the peptide array platform provided a means to comprehensively study the 
rapid changes in the kinome of NSCs and R6/2 mice, to investigate the pathways dysregulated in 
the disease. The most significant pathway dysregulated in kinome analysis was cytoskeletal 
signaling.  It is evident that this data is purely correlative, but it does offer intriguing insight into 
disease progression, at least preliminarily, and implicates the activation of apoptotic pathways, 
calcium signaling and ROS generation as causative or adaptive mechanisms in the dysregulated 
cytoskeletal dynamics. Profilin balances the F/G actin ratio which ultimately affects the actin 
polymerization and its activation leads to the leads to the aggregation of mHtt. Overall these results 
indicate that the LIMK1-cofilin-SSH1L dynamics are affected in HD, and that they most likely 
underlie a reduction in neurite outgrowth (Figure 6.1). This was corroborated by the Neurolucida 
360 analysis shown earlier, where there is a 25% reduction in the neurite length in HD compared 
to controls (Figure 4.5). Any alterations in cellular cytoskeletal dynamics would clearly have an 
impact on cellular morphology, transport and synaptic integrity, which would contribute to a 
degenerative phenotype and neuronal cell death. Thus, the data provides therapeutic targets for 
treating the disease phenotype. Overall, this temporal study furthered knowledge of the 
dysregulation of cytoskeletal abnormalities in HD across key developmental time points, and 
opened avenues for further research in discovering targets for therapeutic intervention.    
 
 
Figure 6.1: Schematic representation of cytoskeletal signaling resulting in neurite reduction 
in HD. 
LIMK1-Cofilin-SSH1L dynamics are affected in HD, and they most likely underlie the reduction 
in neurite outgrowth by affecting the actin polymerization. 
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7. FUTURE DIRECTIONS 
           
7.1 Kinome analysis of other neural tissues 
 
          Striatum is the most affected tissue in HD, and based on the kinome analysis, it would be 
interesting to assess the differential phosphorylation status of the same peptides in other neural 
tissues, including the cortex, hippocampus and cerebellum. Multiple studies have shown that both 
the striatum and cortex are the most affected tissue subtypes in HD. Most of such research has 
focused on specific time points, sexes, or large-scale studies that provide data that are relevant to 
the particular stage of disease, sex, or tissue type. If the key developmental stages in a progressive 
disease such as HD are missing, the data obtained will be incomplete for the development of 
therapeutic strategies. Moreover, variations in the number of polyQ repeats affects the onset of 
disease; thus, complicating the understanding of the disease process and the identification of 
possible differences between the two sexes. All such factors must also be addressed by future 
studies. Different neural tissues have different functions, and thus, the combined kinome dataset 
of all tissues will allow us to better understand the development of disease and disentangle the 
cross-talk between signaling mechanisms affected at various stages of disease.  
 
7.2 Stem cells 
 
            A common approach to investigating the human disease to find therapeutic targets is by 
performing preliminary experiments using animal models. Rodents are cost effective and an easy 
option though they are not the perfect model to recapitulate all aspects of human diseases. 
Nonetheless these models cover a wide range of symptoms of the neurodegenerative condition and 
allow a better understanding of the disease. Brain pathologies alter the expression of a number of 
genes and as the different cell types have specific function these molecular changes contribute to 
cognitive decline and behavioral deficits. The molecular mechanisms in a murine model will 
definitely be different when compared to a human. The R6/2 transgenic mice contain the exon 1 
of the human HD gene with the polyQ repeats. They do not have the genetic background of a 
human, a reason for why a number of clinical trials have failed.  
            As discussed previously, the complexity in understanding HD is due to a number of 
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reasons. i) The different polyQ repeats affects the onset of disease; ii) possible differences in both 
sexes; and iii) the interplay between the different neural tissues. Personalized medicine is the future 
of medical practice and HD is ideal candidate.  This is so since the repeat size varies among the 
patients and the disease is more aggressive when inherited from the father as discussed earlier. 
Since the discovery of the HD gene 25 years ago, the first massive clinical trial to study the effect 
of a mHtt-lowering drug (RG6042) are about to begin at specific centers around the globe 
(Mullard, 2019). However, it remains important to understand the subtleties in the disease that 
cause differences between patients. Patient derived NSCs could play a large role in understanding 
such subtle differences and facilitate the development of therapeutic strategies (Yamanaka and 
Blau, 2010). This observational study provided data from the NSCs of one female HD patient with 
a specific number of polyQ repeats, but a higher number of such patient lines would advance the 
development of therapeutics and promote an understanding of the complexities. The inclusion of 
a larger number of patient derived stem cell lines will also enhance patient specific data, which 
will ultimately assist in dose response and reduced animal trials to achieve the desired results.  
 
7.3 Therapeutic strategies  
 
            A recent study showed that intranasal administration of mesenchymal stem cells at four 
weeks ameliorated the HD phenotype in R6/2 HD mice (Yu-Taeger et al., 2019). They used a non-
invasive surgical procedure and utilized the regenerative properties of multipotent mesenchymal 
stem cells (MSCs) and their ability to migrate to degenerating central nervous system (Yu-Taeger 
et al., 2019).  
            This thesis indicates a dysregulated cytoskeletal dynamics and potential for therapeutic 
intervention. Based on the results of the kinome analysis cofilin / profilin or LIMK1/SSH1L 
combined therapeutic strategy could be exploited at E14. If cofilin / profilin inhibitors or LIMK1 
activator and SSH1L inhibitor is given to a R6/2 mouse as a combination therapeutic it might result 
in the formation of proper synaptic connections. This might be able to regulate the kinase signaling 
in HD due to the mutant protein therefore delaying the appearance of symptoms. This along with 
reducing the accumulation of mutant protein later in life might be beneficial, ameliorating the 
disease phenotype. Such a trial in a well-established mouse model such as R6/2 can be exploited 
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Supplementary Table 1: List of peptides from a previously designed peptide array with peptides 
their uniprot ID and phosphosites. This array was used to study signaling changes in the NSCs. 
 
Supplementary Table 2:  PIIKA 2 output from the peptide array experiment for NSCs. Columns 
represents the name, uniprot ID, target phosphosite followed by their respective P-value and fold 
change.  
 
Supplementary Table 3: InnateDB output for the peptide array analysis of NSCs. The first sheet 
represents the output for upregulated peptides (up) and the second sheet downregulated peptides 
(down). 
 
Supplementary Table 4: List of peptides for the customized peptide array to study the kinase 
signaling in R6/2 neural tissue. The name of the peptide is followed by it uniprot ID and target 
phosphosite.  
 
Supplementary Table 5: PIIKA 2 output from the peptide array experiment for murine neural 
tissue. Columns represents the name, uniprot ID, target phosphosite followed by their respective 
P-value and fold change. Each time point and sex is represented in a separate sheet. 
 
Supplementary Table 6: InnateDB output for the peptide array analysis of murine neural tissues. 
The excel sheet represents the output for upregulated peptides. Each time point and sex is 
represented in a separate sheet. 
 
Supplementary Table 7: InnateDB output for the peptide array analysis of murine neural tissues. 
The excel sheet represents the output for downregulated peptides. Each time point and sex is 
represented in a separate sheet. 
 
Supplementary Table 8: List of predicted kinases identified by NetworKIN. Shown in this Table 
are the predicted kinases for upregulated and downregulated peptides. They are further divided 
based on sex and the eight time points of the study. The predicted kinases are ranked based on the 






Supplementary Figure 1.1. Identification of candidate kinases predicted to target the 
upregulated and downregulated phosphosites in the striatal tissue of R6/2 HD mice at 
embryonic day 9:  Dendrogram of the human kinome constructed using KinMap (Eid et al., 2017), 
highlighting the candidate kinases predicted to target the upregulated and downregulated 
phosphosites in the whole brain of females (A) and males (B) at embryonic day 9 (E9). Candidate 
kinases were identified by NetworKIN (Linding et al., 2007) analysis. Red=upregulated, 











Supplementary Figure 1.2. Identification of candidate kinases predicted to target the 
upregulated and downregulated phosphosites in the striatal tissue of R6/2 HD mice at 
embryonic day 14:  Dendrogram of the human kinome constructed using KinMap (Eid et al., 
2017), highlighting the candidate kinases predicted to target the upregulated and downregulated 
phosphosites in the whole brain of females (A) and males (B) at embryonic day 14 (E14). 
Candidate kinases were identified by NetworKIN (Linding et al., 2007) analysis. 
Red=upregulated, Green=downregulated, Blue=upregulated in either M/F, Yellow= 








Supplementary Figure 1.3. Identification of candidate kinases predicted to target the 
upregulated and downregulated phosphosites in the striatal tissue of newborn R6/2 HD mice: 
Dendrogram of the human kinome constructed using KinMap (Eid et al., 2017), highlighting the 
candidate kinases predicted to target the upregulated and downregulated phosphosites in the 
striatal tissue of females (A) and males (B) at birth (P0). Candidate kinases were identified by 
NetworKIN (Linding et al., 2007) analysis. Red=upregulated, Green=downregulated, 







Supplementary Figure 1.4. Identification of candidate kinases predicted to target the 
upregulated and downregulated phosphosites in the striatal tissue of 3-week-old R6/2 HD 
mice:  Dendrogram of the human kinome constructed using KinMap (Eid et al., 2017), 
highlighting the candidate kinases predicted to target the upregulated and downregulated 
phosphosites in the striatal tissue of females (A) and males (B) at week 3 (3w). Candidate kinases 
were identified by NetworKIN (Linding et al., 2007) analysis. Red=upregulated, 









Supplementary Figure 1.5 Identification of candidate kinases predicted to target the 
upregulated and downregulated phosphosites in the striatal tissue of 4-week-old R6/2 HD 
mice:  Dendrogram of the human kinome constructed using KinMap (Eid et al., 2017), 
highlighting the candidate kinases predicted to target the upregulated and downregulated 
phosphosites in the striatal tissue of females (A) and males (B) at week 4 (4w). Candidate kinases 
were identified by NetworKIN (Linding et al., 2007) analysis. Red=upregulated, 










Supplementary Figure 1.6 Identification of candidate kinases predicted to target the 
upregulated and downregulated phosphosites in the striatal tissue of 5-week-old R6/2 HD 
mice:  Dendrogram of the human kinome constructed using KinMap (Eid et al., 2017), 
highlighting the candidate kinases predicted to target the upregulated and downregulated 
phosphosites in the striatal tissue of females (A) and males (B) at week 5 (5w). Candidate kinases 
were identified by NetworKIN (Linding et al., 2007) analysis. Red=upregulated, 









Supplementary Figure 1.7 Identification of candidate kinases predicted to target the 
upregulated and downregulated phosphosites in the striatal tissue of 7-week-old R6/2 HD 
mice:  Dendrogram of the human kinome constructed using KinMap (Eid et al., 2017), 
highlighting the candidate kinases predicted to target the upregulated and downregulated 
phosphosites in the striatal tissue of females (A) and males (B) at week 7 (7w). Candidate kinases 
were identified by NetworKIN (Linding et al., 2007) analysis. Red=upregulated, 










Supplementary Figure 1.8 Identification of candidate kinases predicted to target the 
upregulated and downregulated phosphosites in the striatal tissue of 10-week-old R6/2 HD 
mice:  Dendrogram of the human kinome constructed using KinMap (Eid et al., 2017), 
highlighting the candidate kinases predicted to target the upregulated and downregulated 
phosphosites in the striatal tissue of females (A) and males (B) at week 10 (10w). Candidate 
kinases were identified by NetworKIN (Linding et al., 2007) analysis. Red=upregulated, 
Green=downregulated, Blue=upregulated in either M/F, Yellow= downregulated in either M/F. 
 
 
 
 
 
 
 
 
 
